<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:25:38Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9671834" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9671834</identifier>
        <datestamp>2023-01-10</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="acem14589" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Acad Emerg Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Acad Emerg Med</journal-id>
              <journal-id journal-id-type="doi">10.1111/(ISSN)1553-2712</journal-id>
              <journal-id journal-id-type="publisher-id">ACEM</journal-id>
              <journal-title-group>
                <journal-title>Academic Emergency Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1069-6563</issn>
              <issn pub-type="epub">1553-2712</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9671834</article-id>
              <article-id pub-id-type="pmcid">PMC9671834</article-id>
              <article-id pub-id-type="pmc-uid">9671834</article-id>
              <article-id pub-id-type="pmid">36047646</article-id>
              <article-id pub-id-type="pmid">36047646</article-id>
              <article-id pub-id-type="doi">10.1111/acem.14589</article-id>
              <article-id pub-id-type="publisher-id">ACEM14589</article-id>
              <article-id pub-id-type="other">AEMJ-22-420.R2</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Contribution</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Contributions</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Point‐of‐care echocardiography of the right heart improves acute heart failure risk stratification for low‐risk patients: The <styled-content style="fixed-case" toggle="no">REED‐AHF</styled-content> prospective study</article-title>
              </title-group>
              <contrib-group>
                <contrib id="acem14589-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Harrison</surname>
                    <given-names>Nicholas E.</given-names>
                  </name>
                  <degrees>MD MSc</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8331-7833</contrib-id>
                  <xref rid="acem14589-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="acem14589-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>harrisne@iu.edu</email>
                    <email>nicholasharrison@wayne.edu</email>
                  </address>
                </contrib>
                <contrib id="acem14589-cr-0002" contrib-type="author">
                  <name>
                    <surname>Favot</surname>
                    <given-names>Mark J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="acem14589-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="acem14589-cr-0003" contrib-type="author">
                  <name>
                    <surname>Gowland</surname>
                    <given-names>Laura</given-names>
                  </name>
                  <degrees>RDCS</degrees>
                  <xref rid="acem14589-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="acem14589-cr-0004" contrib-type="author">
                  <name>
                    <surname>Lenning</surname>
                    <given-names>Jacob</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="acem14589-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="acem14589-cr-0005" contrib-type="author">
                  <name>
                    <surname>Henry</surname>
                    <given-names>Sarah</given-names>
                  </name>
                  <degrees>PA‐C MS‐3</degrees>
                  <xref rid="acem14589-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="acem14589-cr-0006" contrib-type="author">
                  <name>
                    <surname>Gupta</surname>
                    <given-names>Sushane</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="acem14589-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="acem14589-cr-0007" contrib-type="author">
                  <name>
                    <surname>Abidov</surname>
                    <given-names>Aiden</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="acem14589-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="acem14589-cr-0008" contrib-type="author">
                  <name>
                    <surname>Levy</surname>
                    <given-names>Phillip</given-names>
                  </name>
                  <degrees>MD MPH</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7306-5620</contrib-id>
                  <xref rid="acem14589-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="acem14589-cr-0009" contrib-type="author">
                  <name>
                    <surname>Ehrman</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <degrees>MD MSc</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9730-8471</contrib-id>
                  <xref rid="acem14589-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="acem14589-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <institution>Indiana University School of Medicine</institution>
                <city>Indianapolis</city>
                <named-content content-type="country-part">Indiana</named-content>
                <country country="US">USA</country>
              </aff>
              <aff id="acem14589-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <institution>Wayne State University</institution>
                <city>Detroit</city>
                <named-content content-type="country-part">Michigan</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Nicholas E. Harrison, Indiana University School of Medicine, Indianapolis, IN 46202, USA.<break/>
Email: <email>harrisne@iu.edu</email>; <email>nicholasharrison@wayne.edu</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>26</day>
                <month>9</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>11</month>
                <year>2022</year>
              </pub-date>
              <volume>29</volume>
              <issue seq="40">11</issue>
              <issue-id pub-id-type="doi">10.1111/acem.v29.11</issue-id>
              <fpage>1306</fpage>
              <lpage>1319</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>23</day>
                  <month>8</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>02</day>
                  <month>6</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>26</day>
                  <month>8</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--Copyright &#x000a9; 2022 Society for Academic Emergency Medicine-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">Academic Emergency Medicine</italic> published by Wiley Periodicals LLC on behalf of Society for Academic Emergency Medicine.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:ACEM-29-1306.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="acem14589-sec-0001">
                  <title>Objectives</title>
                  <p>Validated acute heart failure (AHF) clinical decision instruments (CDI) insufficiently identify low‐risk patients meriting consideration of outpatient treatment. While pilot data show that tricuspid annulus plane systolic excursion (TAPSE) is associated with adverse events, no AHF CDI currently incorporates point‐of‐care echocardiography (POCecho). We evaluated whether TAPSE adds incremental risk stratification value to an existing CDI.</p>
                </sec>
                <sec id="acem14589-sec-0002">
                  <title>Methods</title>
                  <p>Prospectively enrolled patients at two urban‐academic EDs had POCechos obtained before or &lt;1 h after first intravenous diuresis, positive pressure ventilation, and/or nitroglycerin. STEMI and cardiogenic shock were excluded. AHF diagnosis was adjudicated by double‐blind expert review. TAPSE, with an a priori cutoff of ≥17 mm, was our primary measure. Secondary measures included eight additional right heart and six left heart POCecho parameters. STRATIFY is a validated CDI predicting 30‐day death/cardiopulmonary resuscitation, mechanical cardiac support, intubation, new/emergent dialysis, and acute myocardial infarction or coronary revascularization in ED AHF patients. Full (STRATIFY + POCecho variable) and reduced (STRATIFY alone) logistic regression models were fit to calculate adjusted odds ratios (aOR), category‐free net reclassification index (NRI<sub>cont</sub>), ΔSensitivity (NRI<sub>events</sub>), and ΔSpecificity (NRI<sub>nonevents</sub>). Random forest assessed variable importance. To benchmark risk prediction to standard of care, ΔSensitivity and ΔSpecificity were evaluated at risk thresholds more conservative/lower than the actual outcome rate in discharged patients.</p>
                </sec>
                <sec id="acem14589-sec-0003">
                  <title>Results</title>
                  <p>A total of 84/120 enrolled patients met inclusion and diagnostic adjudication criteria. Nineteen percent experiencing the primary outcome had higher STRATIFY scores compared to those event free (233 vs. 212, <italic toggle="no">p</italic> = 0.009). Five right heart (TAPSE, TAPSE/PASP, TAPSE/RVDD, RV‐FAC, fwRVLS) and no left heart measures improved prediction (<italic toggle="no">p</italic> &lt; 0.05) adjusted for STRATIFY. Right heart measures also had higher variable importance. TAPSE ≥ 17 mm plus STRATIFY improved prediction versus STRATIFY alone (aOR 0.24, 95% confidence interval [CI] 0.06–0.91; NRI<sub>cont</sub> 0.71, 95% CI 0.22–1.19), and specificity improved by 6%–32% (<italic toggle="no">p</italic> &lt; 0.05) at risk thresholds more conservative than the standard‐of‐care benchmark without missing any additional events.</p>
                </sec>
                <sec id="acem14589-sec-0004">
                  <title>Conclusions</title>
                  <p>TAPSE increased detection of low‐risk AHF patients, after use of a validated CDI, at risk thresholds more conservative than standard of care.</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="acem14589-kwd-0001">cardiology</kwd>
                <kwd id="acem14589-kwd-0002">echocardiography</kwd>
                <kwd id="acem14589-kwd-0003">emergency department</kwd>
                <kwd id="acem14589-kwd-0004">emergency medicine</kwd>
                <kwd id="acem14589-kwd-0005">heart failure</kwd>
                <kwd id="acem14589-kwd-0006">point‐of‐care ultrasound</kwd>
                <kwd id="acem14589-kwd-0007">risk stratification</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>Blue Cross Blue Shield of Michigan Foundation
</institution>
                      <institution-id institution-id-type="doi">10.13039/100001502</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>Investigator Initiated Grant Program, 2019</award-id>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award</funding-source>
                  <award-id>KL2TR002530</award-id>
                  <award-id>UL1TR002529</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="3"/>
                <page-count count="14"/>
                <word-count count="9242"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>November 2022</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.3 mode:remove_FC converted:09.01.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="ACEM14589-cit-2001"><string-name><surname>Harrison</surname><given-names>NE</given-names></string-name>, <string-name><surname>Favot</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Gowland</surname><given-names>L</given-names></string-name>, et al. <article-title>Point‐of‐care echocardiography of the right heart improves acute heart failure risk stratification for low‐risk patients: The <styled-content style="fixed-case" toggle="no">REED‐AHF</styled-content> prospective study</article-title>. <source>Acad Emerg Med</source>. <year>2022</year>;<volume>29</volume>:<fpage>1306</fpage>‐<lpage>1319</lpage>. doi: <pub-id pub-id-type="doi">10.1111/acem.14589</pub-id>
<pub-id pub-id-type="pmid">36047646</pub-id></mixed-citation>
              </p>
              <fn-group id="acem14589-ntgp-0001">
                <fn id="acem14589-note-0001">
                  <p>Supervising Editor: Dr. Brian Hiestand</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="acem14589-body-0001">
            <sec id="acem14589-sec-0005">
              <title>INTRODUCTION</title>
              <p>Acute heart failure (AHF) accounts for 1 million emergency department (ED) visits annually<xref rid="acem14589-bib-0001" ref-type="bibr"><sup>1</sup></xref> and presents significant dilemmas for risk stratification and ED disposition.<xref rid="acem14589-bib-0002" ref-type="bibr"><sup>2</sup></xref> Over 80% of AHF patients treated in United States EDs are admitted to the hospital, but as many as half may be low enough risk to avoid admission.<xref rid="acem14589-bib-0003" ref-type="bibr"><sup>3</sup></xref>, <xref rid="acem14589-bib-0004" ref-type="bibr"><sup>4</sup></xref>, <xref rid="acem14589-bib-0005" ref-type="bibr"><sup>5</sup></xref>, <xref rid="acem14589-bib-0006" ref-type="bibr"><sup>6</sup></xref> The forthcoming 2022 update to the American College of Emergency Physicians (ACEP) clinical policy on AHF<xref rid="acem14589-bib-0007" ref-type="bibr"><sup>7</sup></xref> identified three validated clinical decision instruments (CDI)<xref rid="acem14589-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="acem14589-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="acem14589-bib-0010" ref-type="bibr"><sup>10</sup></xref> that are useful for risk‐stratification: the STRATIFY risk score,<xref rid="acem14589-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="acem14589-bib-0011" ref-type="bibr"><sup>11</sup></xref> the Emergency Heart Failure Mortality Risk Grade (EHMRG),<xref rid="acem14589-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="acem14589-bib-0012" ref-type="bibr"><sup>12</sup></xref> and the Ottawa Heart Failure Risk Scale (OHFRS).<xref rid="acem14589-bib-0010" ref-type="bibr"><sup>10</sup></xref>, <xref rid="acem14589-bib-0013" ref-type="bibr"><sup>13</sup></xref> While all three have validation test characteristics that exceed published performance of emergency physician (EP)‐estimated risk<xref rid="acem14589-bib-0009" ref-type="bibr"><sup>9</sup></xref> and actual disposition decisions,<xref rid="acem14589-bib-0012" ref-type="bibr"><sup>12</sup></xref> none were deemed sufficient to direct AHF disposition on their own. Recent multicenter studies have shown that ED discharged AHF patients experience 30‐day rates of death (3.8%)<xref rid="acem14589-bib-0014" ref-type="bibr"><sup>14</sup></xref> and serious adverse events (7.1%) in STRATIFY's composite outcome<xref rid="acem14589-bib-0006" ref-type="bibr"><sup>6</sup></xref> much greater than risk thresholds that EPs report as acceptable.<xref rid="acem14589-bib-0015" ref-type="bibr"><sup>15</sup></xref> Nonetheless, in one study comparing EHMRG<xref rid="acem14589-bib-0009" ref-type="bibr"><sup>9</sup></xref> to EP‐estimated risk, not only did EHRMG perform significantly better but EPs frequently misclassified the highest risk patients as low risk (and vice versa). Given this, recent SAEM‐endorsed expert consensus guidelines have identified “safely transitioning a larger proportion of patients to the outpatient setting”<xref rid="acem14589-bib-0016" ref-type="bibr"><sup>16</sup></xref> and “prediction of low risk”<xref rid="acem14589-bib-0005" ref-type="bibr"><sup>5</sup></xref> as critical needs in AHF clinical research.</p>
              <p>In a previous pilot study we identified that tricuspid annulus plane systolic excursion (TAPSE) on EP‐performed point‐of‐care echocardiography (POCecho) is associated with short‐term adverse AHF events.<xref rid="acem14589-bib-0017" ref-type="bibr"><sup>17</sup></xref> This compares to numerous studies of HF patients outside the ED setting, where TAPSE and other measures of right ventricular dysfunction (RVD) and/or pulmonary hypertension (PH) predict adverse outcomes,<xref rid="acem14589-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="acem14589-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="acem14589-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="acem14589-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="acem14589-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="acem14589-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="acem14589-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="acem14589-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="acem14589-bib-0026" ref-type="bibr"><sup>26</sup></xref>, <xref rid="acem14589-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="acem14589-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="acem14589-bib-0029" ref-type="bibr"><sup>29</sup></xref> often more strongly than LV dysfunction<xref rid="acem14589-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="acem14589-bib-0031" ref-type="bibr"><sup>31</sup></xref>, <xref rid="acem14589-bib-0032" ref-type="bibr"><sup>32</sup></xref>, <xref rid="acem14589-bib-0033" ref-type="bibr"><sup>33</sup></xref>, <xref rid="acem14589-bib-0034" ref-type="bibr"><sup>34</sup></xref>, <xref rid="acem14589-bib-0035" ref-type="bibr"><sup>35</sup></xref>, <xref rid="acem14589-bib-0036" ref-type="bibr"><sup>36</sup></xref>, <xref rid="acem14589-bib-0037" ref-type="bibr"><sup>37</sup></xref>, <xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref>, <xref rid="acem14589-bib-0039" ref-type="bibr"><sup>39</sup></xref>, <xref rid="acem14589-bib-0040" ref-type="bibr"><sup>40</sup></xref>, <xref rid="acem14589-bib-0041" ref-type="bibr"><sup>41</sup></xref>, <xref rid="acem14589-bib-0042" ref-type="bibr"><sup>42</sup></xref> or biomarkers.<xref rid="acem14589-bib-0037" ref-type="bibr"><sup>37</sup></xref>, <xref rid="acem14589-bib-0042" ref-type="bibr"><sup>42</sup></xref>, <xref rid="acem14589-bib-0043" ref-type="bibr"><sup>43</sup></xref>, <xref rid="acem14589-bib-0044" ref-type="bibr"><sup>44</sup></xref>, <xref rid="acem14589-bib-0045" ref-type="bibr"><sup>45</sup></xref>, <xref rid="acem14589-bib-0046" ref-type="bibr"><sup>46</sup></xref> Conversely, there is a stark absence of prior ED risk stratification studies that incorporate or consider echocardiography measures. Nevertheless, TAPSE<xref rid="acem14589-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref>, <xref rid="acem14589-bib-0047" ref-type="bibr"><sup>47</sup></xref>, <xref rid="acem14589-bib-0048" ref-type="bibr"><sup>48</sup></xref>, <xref rid="acem14589-bib-0049" ref-type="bibr"><sup>49</sup></xref> and other right heart measures<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref>, <xref rid="acem14589-bib-0050" ref-type="bibr"><sup>50</sup></xref> have been used by EPs with high interobserver reliability in the risk stratification of pulmonary embolus, suggesting feasibility for AHF risk stratification.</p>
              <p>The Right ventricular Echocardiography in ED AHF (REED‐AHF) study was a two‐center prospective cohort<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> whose primary objective was to evaluate if ED TAPSE had additive and incremental predictive value for 30‐day serious adverse events when used in conjunction with a validated and ACEP‐endorsed CDI such as STRATIFY. We hypothesized that TAPSE, at an a priori ≥ 17‐mm cutoff from our pilot study,<xref rid="acem14589-bib-0017" ref-type="bibr"><sup>17</sup></xref> would improve risk stratification for STRATIFY's 30‐day composite of serious adverse AHF events compared to STRATIFY alone. Secondarily, we sought to characterize the incremental value of 14 additional POCecho measures for the same purpose and evaluate how these alternative measures compare to TAPSE by variable importance and predictive value after adjusting for STRATIFY.</p>
            </sec>
            <sec sec-type="methods" id="acem14589-sec-0006">
              <title>METHODS</title>
              <p>The primary methods, protocol, design, and patient cohort of REED‐AHF have been described previously.<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> REED‐AHF was funded by an investigator‐initiated grant (NH) from the Blue Cross Blue Shield Foundation of Michigan and approved by the Wayne State University Institutional Review Board. This report describes the primary aim of the study. This report has been prepared to adhere to the STROBE guidelines.<xref rid="acem14589-bib-0051" ref-type="bibr"><sup>51</sup></xref>
</p>
              <sec id="acem14589-sec-0007">
                <title>Study design, setting, and population</title>
                <p>REED‐AHF was a prospective multicenter cohort study at two urban EDs with 80,000–100,000 annual visits each. Detroit Receiving Hospital is an urban‐academic referral hospital and Level I trauma center; Sinai‐Grace Hospital is an urban‐community Level II trauma center. Both sites host 3‐year emergency medicine (EM) residencies.</p>
                <p>Patients were enrolled from September 2019 to February 2020 and November 2020 through March 2021. Enrollment was paused during the intervening 8 months per institutional policies regarding clinical research during the early phase of the COVID‐19 pandemic. Patients were screened 7 days per week by trained research staff and study personnel; however, enrollment was limited to times when a study sonographer was available.<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> Despite this, 25% of patients were enrolled between the hours of 5 p.m. and 8 a.m. and 18% on weekends.<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref>
</p>
                <p>Full inclusion, exclusion, and diagnostic adjudication criteria have been described previously.<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> Patients with cardiogenic shock, STEMI, tachydysrhythmia requiring intravenous (IV) rate control and those deemed not to have AHF by the EP at disposition were excluded. Patients had to receive a POCecho and lung ultrasound (LUS) within &lt;1 h after, or any time before, first initiation of any qualifying AHF treatment: IV loop diuretics, SL or IV nitroglycerin, noninvasive positive pressure ventilation (NIPPV), and/or intubation. Two experts (AA, MF) blinded to study outcomes adjudicated the ED diagnosis of AHF.<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref>
</p>
              </sec>
              <sec id="acem14589-sec-0008">
                <title>Study protocol</title>
                <p>The POCecho protocol, performed using a Vivid q ultrasound system, has been described previously.<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> A majority of POCechos were performed by a single EP sonographer (NH) without POCUS fellowship training, with fewer performed by a POCUS‐trained co‐investigator (RE or MF), PGY‐2 EM resident (JL), or research cardiac sonographer (LG). Measurements were made first on the POC platform. A second offline measurement by a different investigator<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> blinded to the POC measures and clinical outcomes was also performed, to allow calculation of intraclass correlation (ICC) for all measures. All POCecho measures (see list of specific measures below) except RVOT acceleration time showed moderate–high inter‐rater reliability (ICC &gt; 0.7) between POC and offline analysis. Per protocol,<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> RVOT acceleration time was then overread by a testamur (RE) of the examination of special competence in adult echocardiography administered by the National Board of Echocardiography (NBE). Another NBE testamur (MF) performed blinded overreads of the free‐wall right ventricular longitudinal strain (fwRVLS) measure on account of this being a more advanced echo measure, yielding ICC &gt; 0.7.</p>
              </sec>
              <sec id="acem14589-sec-0009">
                <title>Primary clinical risk measure: the <styled-content style="fixed-case" toggle="no">STRATIFY</styled-content> risk score</title>
                <p>Demographic and clinical variables were collected prospectively at enrollment, throughout hospitalization, and through 90‐day follow‐up as previously described.<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> The primary ED clinical measure of interest was the STRATIFY score,<xref rid="acem14589-bib-0008" ref-type="bibr"><sup>8</sup></xref> and its component variables of age, BMI, brain natriuretic peptide, blood urea nitrogen, dialysis history, diastolic blood pressure, sodium, ED supplemental oxygen requirement, outpatient ACE inhibitor, QRS prolongation on electrocardiogram, respiratory rate, oxygen saturation, and cardiac troponin I.</p>
                <p>STRATIFY was chosen as the primary clinical risk measure for a few reasons. First, as cited above, it is one of three CDIs endorsed by ACEP to be helpful in risk stratification.<xref rid="acem14589-bib-0007" ref-type="bibr"><sup>7</sup></xref> Second, compared to EHMRG and OHFRS, it contains the largest number and greatest diversity of clinical variables which an EP may use and have access to in clinical decision making. Third, STRATIFY was derived to predict a hierarchical composite of several serious adverse AHF events which all have clinical significance (described below).<xref rid="acem14589-bib-0008" ref-type="bibr"><sup>8</sup></xref>
</p>
              </sec>
              <sec id="acem14589-sec-0010">
                <title>Primary clinical outcome</title>
                <p>The primary clinical outcome was the 30‐day composite of serious adverse AHF events which STRATIFY was derived<xref rid="acem14589-bib-0008" ref-type="bibr"><sup>8</sup></xref> and then validated<xref rid="acem14589-bib-0011" ref-type="bibr"><sup>11</sup></xref> to predict. The composite includes death/CPR, mechanical cardiac support, intubation, new or emergent dialysis, and/or acute myocardial infarction (AMI)/percutaneous coronary intervention (PCI)/coronary artery bypass grafting (CABG). Previous validation<xref rid="acem14589-bib-0011" ref-type="bibr"><sup>11</sup></xref> showed STRATIFY to predict this outcome with &gt;0.7 area under the receiver operating characteristic curve (AUROC).</p>
                <p>Outcomes were adjudicated by telephone follow‐up, supplemented by multiple blinded abstractors reviewing electronic medical record data and health information exchange data for the state of Michigan as previously described.<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> AMI was defined based on the Fourth Universal Definition of MI,<xref rid="acem14589-bib-0052" ref-type="bibr"><sup>52</sup></xref> adjudicated by multiple blinded raters.</p>
              </sec>
              <sec id="acem14589-sec-0011">
                <title>Data analysis</title>
                <p>All statistical analyses were performed in the R language (R Studio 2021.09.1). Patient characteristics were stratified by those with versus without the primary outcome, and echocardiography parameters by outcome and ED disposition, to calculate descriptive statistics using the Wilcoxon rank‐sum test for continuous variables and Fisher's exact test for categorical variables (α = 0.05).</p>
                <sec id="acem14589-sec-0012">
                  <title>Primary echo measure</title>
                  <p>Based on our pilot study which showed association between adverse events and TAPSE &lt; 17mm<xref rid="acem14589-bib-0017" ref-type="bibr"><sup>17</sup></xref> and other published data in non‐ED settings, our primary measure of interest was TAPSE, which was analyzed as a continuous variable with an a priori binary cutoff of ≥17 mm. To provide 80% power to detect an adjusted odds ratio (aOR) of 0.30 at this cutoff for prediction of the primary outcome, 111 patients were needed.</p>
                </sec>
                <sec id="acem14589-sec-0013">
                  <title>Secondary <styled-content style="fixed-case" toggle="no">POCecho</styled-content> measures for comparison and exploratory analysis</title>
                  <p>Additional right heart measures included fwRVLS, RV‐LV ratio, pulmonary artery systolic pressure (PASP) by tricuspid regurgitant jet velocity (i.e., which is also the right ventricular systolic pressure [RVSP] under most scenarios}, TAPSE/PASP ratio, TAPSE/right ventricular diastolic diameter ratio (TAPSE/RVDD), RV fractional area change (FAC), pulmonary vascular resistance, and RVOT acceleration time. Left heart measures included left ventricular ejection fraction (LVEF), mitral E/A ratio, septal E', lateral E', E/E' ratio, and LV global longitudinal strain (LVGLS) by speckle tracking.</p>
                  <p>Exploratory analyses were conducted with two goals. First, we explored the possibility that measures besides TAPSE may have incremental value in risk stratification, since few descriptions of any POCecho measure exist in ED‐based AHF risk stratification literature. Second, the other measures served as indirect comparators to TAPSE in evaluating our primary hypothesis. We approached comparison in two ways: (1) evaluating relative variable importance of all POCecho measures with STRATIFY in a random forest model and (2) modeling each POCecho variable in the same way as TAPSE in full (POCecho measure plus STRATIFY) and reduced (STRATIFY only) logistic regression models for measures of incremental improvement in prediction (logistic regression methods, below). Secondary POCecho measures were also analyzed as continuous variables and using a priori binary cutoffs corresponding to the American Society of Echocardiography guidelines<xref rid="acem14589-bib-0053" ref-type="bibr"><sup>53</sup></xref>, <xref rid="acem14589-bib-0054" ref-type="bibr"><sup>54</sup></xref>, <xref rid="acem14589-bib-0055" ref-type="bibr"><sup>55</sup></xref> or, in the absence of a guideline‐recommended value, prior AHF literature from settings outside the ED.<xref rid="acem14589-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="acem14589-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="acem14589-bib-0026" ref-type="bibr"><sup>26</sup></xref>, <xref rid="acem14589-bib-0056" ref-type="bibr"><sup>56</sup></xref>, <xref rid="acem14589-bib-0057" ref-type="bibr"><sup>57</sup></xref>
</p>
                </sec>
                <sec id="acem14589-sec-0014">
                  <title>Importance by random forest</title>
                  <p>The random forest model for assessing variable importance was run under the following specifications: (1) all 15 echo variables including TAPSE and the STRATIFY score were able to be incorporated into classification trees; (2) no more than two total variables (STRATIFY, plus one POCecho variable) were allowed to be sampled in a single classification tree (to prevent overfitting from any single model, e.g. incorporating three or more variables); and (3) 10,000 trees were grown for prediction of the clinical primary outcome using the randomForest package in R, with importance (mean decrease in Gini) calculated and plotted. Random forest utilized in this way aids in selection of independent variables (features) in the context of high dimensionality by calculating the importance of each variable in predicting the outcome of interest, of which mean decrease in Gini is a common importance measure.<xref rid="acem14589-bib-0058" ref-type="bibr"><sup>58</sup></xref> The expected outcome was that STRATIFY would rise to the top as the most important overall variable, followed by the POCecho variables of importance after accounting for STRATIFY.</p>
                </sec>
                <sec id="acem14589-sec-0015">
                  <title>Logistic regression and measures of incremental predictive value/improvement</title>
                  <sec id="acem14589-sec-0016">
                    <title>Risk thresholds</title>
                    <p>Reduced (STRATIFY score alone) and full (POCecho measure plus STRATIFY) logistic regression models were fit<xref rid="acem14589-bib-0059" ref-type="bibr"><sup>59</sup></xref> for the primary outcome to calculate unadjusted odds ratios (OR), aOR, and category‐free (i.e., continuous) net reclassification index (NRI<sub>cont</sub>). NRI measures the degree by which addition of a single variable to an existing prediction model improves the classification of that model, focused on the observations which are reclassified to a different prediction category by the added predictor, and specifically whether or not those reclassifications resulted in fewer or greater correct classifications overall (i.e., net).<xref rid="acem14589-bib-0060" ref-type="bibr"><sup>60</sup></xref> The NRI<sub>cont</sub> assesses classification across all risk thresholds, while the categorical NRI assesses reclassification at specific risk cutoffs.<xref rid="acem14589-bib-0060" ref-type="bibr"><sup>60</sup></xref> Variance inflation factor (VIF) was calculated to assess models for multicollinearity; all VIF were &lt; 3. Models were internally validated using the bootstrap to assess optimism and produce bias‐corrected estimates of AUROC,<xref rid="acem14589-bib-0059" ref-type="bibr"><sup>59</sup></xref> so that reported estimates of performance are lower (more conservative) than the observed estimates, to account for the fact that new models tend to perform worse on external validation. Categorical NRI for various risk‐thresholds were calculated separately for events (NRI<sub>events</sub>) and nonevents (NRI<sub>nonevents</sub>) by methods previously described<xref rid="acem14589-bib-0060" ref-type="bibr"><sup>60</sup></xref> to enhance clinical utility and interpretability. Calculated this way, NRI<sub>nonevents</sub> = ΔSpecificity and NRI<sub>events</sub> = ΔSensitivity—i.e., the improvement or worsening in sensitivity and specificity in the standard risk stratification (i.e., STRATIFY score) after adding a novel risk marker (i.e., POCecho variable such as TAPSE)<xref rid="acem14589-bib-0060" ref-type="bibr"><sup>60</sup></xref>; 95% confidence intervals (95%CI) were calculated and reported.</p>
                  </sec>
                </sec>
                <sec id="acem14589-sec-0017">
                  <title>Benchmarking to clinical standard of care decision making</title>
                  <p>There is no currently agreed upon “acceptable” miss rate for serious adverse events at which patients should be considered for outpatient treatment of AHF after ED treatment. To account for this, we benchmarked categorical risk prediction and reclassification to standard‐of‐care risk stratification. Model predicted risk thresholds (i.e., miss rates) were chosen to be below the true/observed rate of the primary outcome among patients actually discharged from the ED by standard EP decision making. Thus, measures of categorical reclassification (NRI<sub>events</sub>/ΔSensitivity and NRI<sub>nonevents</sub>/ΔSpecificity) were calculated at thresholds that would ensure that the model's “miss rate” was more conservative than the standard‐of‐care miss rate. The rationale of this approach was that even if the exact value of an “acceptable miss rate” is debated, most EPs would likely agree that a model which misses fewer events than the standard of care is potentially useful, particularly if it can also increase identification of low risk (i.e., improved NRI<sub>nonevents</sub>/ΔSpecificity) without adding missed events (i.e., no decline in sensitivity).</p>
                  <p>To increase precision in estimating the benchmark standard‐of‐care miss rate, we averaged the rate of events in discharged patients in REED‐AHF<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> with the rate observed in CLEAR‐AHF, a recent 257 prospective patient cohort from the same institution.<xref rid="acem14589-bib-0006" ref-type="bibr"><sup>6</sup></xref> CLEAR‐AHF<xref rid="acem14589-bib-0006" ref-type="bibr"><sup>6</sup></xref> had similar adjudication of AHF diagnosis, adjudicated outcomes for the STRATIFY risk score, and similar inclusion criteria as REED‐AHF, but was larger than REED‐AHF and had slightly lower outcome rates.<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> Among 341 patients in both cohorts, 8.3% of discharged patients experienced the primary outcome compared to 13.6% among admitted or observation patients.<xref rid="acem14589-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> Thus, 8% was chosen as the higher risk threshold to be evaluated (i.e., the least conservative integer risk threshold to still be more conservative than usual care). A low‐end risk threshold of 3% was chosen to match the smallest risk‐threshold for which STRATIFY was derived and validated.<xref rid="acem14589-bib-0008" ref-type="bibr"><sup>8</sup></xref>
</p>
                </sec>
                <sec id="acem14589-sec-0018">
                  <title>Sensitivity analysis: comparison to clinical features not captured by <styled-content style="fixed-case" toggle="no">STRATIFY</styled-content>
</title>
                  <p>Although STRATIFY was chosen as the primary baseline risk measure in part because of how many different clinical variables it incorporates, some important decision‐making factors for EP risk stratification of AHF nevertheless are absent from the risk score. We analyzed several clinical factors not included in STRATIFY that could hypothetically add predictive value. First, past history of chronic obstructive pulmonary disease (COPD), PH, ED systolic blood pressure (SBP), pre‐ED adherence to guideline‐directed medical therapy, and sex were chosen a priori as patient‐level factors that could be associated with both TAPSE and outcomes while not being incorporated in STRATIFY. Several treatment‐level variables were chosen based on being possible therapeutic indications why a patient would not be a candidate for outpatient treatment (i.e., even if low risk for adverse events), including total ED IV furosemide dose, ED NIPPV, ED IV nitroglycerin, and any new or increased oxygen requirement during the ED visit compared to baseline. Finally, EP disposition decisions of discharge versus admission and ICU versus another level of care were included to assess actual clinical decision‐making compared to the POCecho variables. EPs were blinded to all POCecho data during the study, including when selecting disposition.</p>
                  <p>Each of the variables here was tested for NRI<sub>cont</sub> when added to STRATIFY by similar methods as described above for the echocardiography variables in sensitivity analyses. The hypothesis of these sensitivity analyses was that significant improvement in classification by any of these variables compared to STRATIFY alone would diminish the importance of any risk stratification benefit observed for a POCecho variable, since these clinical variables are more easily obtained through history and medical record review than a POCecho, are commonly found in current AHF risk stratification literature and ED‐based CDIs, and/or inherently reflect the standard‐of‐care in EP decision‐making.</p>
                </sec>
              </sec>
            </sec>
            <sec sec-type="results" id="acem14589-sec-0019">
              <title>RESULTS</title>
              <sec id="acem14589-sec-0020">
                <title>Enrollment and time to <styled-content style="fixed-case" toggle="no">POC</styled-content>echo</title>
                <p>A total of 120 patients met initial inclusion criteria, with POCechos obtained at a median of −75 min (interquartile range [IQR] −131 to +13) before first IV loop diuretic, +33 min (+6 to +59) after initiation of PPV, −21 min (−49 to +23) before first IV/SL nitroglycerin, +33 min (−234 to +162) after first supplemental O<sub>2</sub> initiation, and +102 min (+47 to +177) after ED arrival. A CONSORT diagram with enrollment details has been previously published.<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> After exclusions for EP diagnosis at disposition of “not‐AHF” (<italic toggle="yes">n</italic> = 11), failure to obtain consent from the patient or a representative within 24 hours of the POCecho (<italic toggle="yes">n</italic> = 20), and expert‐adjudicated diagnoses of not‐AHF (<italic toggle="yes">n</italic> = 5), 84 patients remained for analysis.</p>
              </sec>
              <sec id="acem14589-sec-0021">
                <title>Descriptive clinical and echocardiographic characteristics</title>
                <p>Description for selected clinical and POCecho measures are presented in Tables <xref rid="acem14589-tbl-0001" ref-type="table">1</xref> and <xref rid="acem14589-tbl-0002" ref-type="table">2</xref>, respectively. Median (IQR) age was 62 (54–70) years, LVEF 28% (19%–38%), TAPSE 17 (13–23) mm, SBP 153 (132–173) mm Hg, and STRATIFY score 215 (198–233). Sixty percent were male (<italic toggle="yes">n</italic> = 50), 18% received NIPPV (<italic toggle="yes">n</italic> = 15), 3.6% (<italic toggle="yes">n</italic> = 3) were admitted to the ICU, 14% (<italic toggle="yes">n</italic> = 12) placed in outpatient observation, and 9.5% (<italic toggle="yes">n</italic> = 8) discharged from the ED.</p>
                <table-wrap position="float" id="acem14589-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Selected clinical characteristics of the cohort</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Characteristic</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Overall, <italic toggle="yes">N</italic> = 84<xref rid="acem14589-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">No 30‐day events, <italic toggle="yes">n</italic> = 68<xref rid="acem14589-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">≥1 event at 30 days, <italic toggle="yes">n</italic> = 16<xref rid="acem14589-note-0003" ref-type="table-fn"><sup>a</sup></xref>
</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"><italic toggle="yes">p</italic>‐value<xref rid="acem14589-note-0004" ref-type="table-fn"><sup>b</sup></xref>
</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" colspan="5" valign="top" rowspan="1">STRATIFY score for ED AHF</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Age (years)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">62 (54–70)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">61 (54–70)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">65 (60–70)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.8</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">BMI</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">28 (24–36)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">30 (23–37)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27 (24–32)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.8</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Brain natriuretic peptide</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1098 (568–1910)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1160 (500–1898)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">688 (615–2151)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">&gt;0.9</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Diastolic blood pressure (mm Hg)–arrival</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">90 (79–101)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">89 (78–100)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">94 (81–108)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.5</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Blood urea nitrogen</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22 (17–36)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22 (17–33)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27 (22–37)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.2</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Sodium</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">138 (136–140)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">139 (137–141)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">136 (134–138)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.001</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Respiratory rate</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20 (20–26)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20 (20–25)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22 (20–32)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.4</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">SpO<sub>2</sub> (%)–arrival</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">97 (95–98)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">96 (95–98)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">99 (96–100)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.11</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Troponin I (ng/mL)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.07 (0.04–0.13)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.07 (0.03–0.12)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.09 (0.07–0.22)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.068</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">History of dialysis</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5 (6.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (2.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (19)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.045</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Any supplemental oxygen in ED</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">47 (56)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">36 (53)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11 (69)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.3</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ACE inhibitor or ARB</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">32 (38)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27 (40)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5 (31)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.5</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Wide QRS on ECG</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17 (20)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13 (19)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4 (25)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.7</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Total ED stratify score</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">215 (198–233)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">212 (196–228)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">233 (218–266)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.009</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="4" valign="top" rowspan="1">Ranked primary outcome (0–5) at 30 days</td>
                        <td rowspan="7" align="left" valign="top" colspan="1">&lt;0.001</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">0 = no 30‐day event</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">68 (81)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">68 (100)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">1 = AMI, PCI, and/or CABG</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8 (9.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8 (50)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">2 = new or emergent dialysis</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (1.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (6.2)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">3 = intubation</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4 (4.8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4 (25)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">4 = mechanical cardiac support</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">5 = Death/CPR</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (3.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (19)</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" valign="top" rowspan="1">Other clinical characteristics<xref rid="acem14589-note-0005" ref-type="table-fn"><sup>c</sup></xref>
</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Systolic blood pressure (mm Hg)–arrival</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">153 (132–173)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">152 (134–170)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">156 (129–184)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.7</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Male sex</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">50 (60)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">39 (57)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11 (69)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.4</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">History of COPD, OSA, or OHS</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">55 (65)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">43 (63)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12 (75)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.4</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">History of pulmonary hypertension</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">27 (32)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">23 (34)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4 (25)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.5</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">IV furosemide (mg)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">ED</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">40 (40–40)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">40 (40–40)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">40 (20–40)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.3</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">24 h</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">80 (40–80)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">80 (40–80)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">40 (40–80)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.058</td>
                      </tr>
                      <tr>
                        <td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Total ED and hospital</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">120 (60–205)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">120 (75–200)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">180 (55–285)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.3</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Total ED and hospital furosemide &gt; 200 mg<xref rid="acem14589-note-0006" ref-type="table-fn"><sup>d</sup></xref>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21 (25)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14 (21)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7 (44)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.1</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Oxygen requirement in ED greater than baseline</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">39 (46)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">30 (44)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9 (56)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.4</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ED NIPPV</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15 (18)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12 (18)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (19)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">&gt;0.9</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Intubated in ED</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (1.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (6.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.2</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ED IV nitroglycerin</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10 (12)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8 (12)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (12)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">&gt;0.9</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="5" valign="top" rowspan="1">ED disposition</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ICU</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3 (3.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2 (2.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (6.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.5</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Observation</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12 (14)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11 (16)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (6.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.4</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Discharged from ED</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8 (9.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7 (10)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1 (6.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">&gt;0.9</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="acem14589-ntgp-0002">
                    <fn id="acem14589-note-0002">
                      <p>Abbreviations: ACE, angiotensin‐converting enzyme; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft; ECG, electrocardiogram; ICU, intensive care unit; NIPPV, noninvasive positive pressure ventilation; PCI, percutaneous coronary intervention; SpO<sub>2</sub>, oxygen saturation.</p>
                    </fn>
                    <fn id="acem14589-note-0003">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Data are reported as median (IQR) or <italic toggle="yes">n</italic> (%).</p>
                    </fn>
                    <fn id="acem14589-note-0004">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Wilcoxon rank‐sum test; Fisher's exact test.</p>
                    </fn>
                    <fn id="acem14589-note-0005">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>See Harrison et al.<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> for a more comprehensive description of the REED‐AHF cohort, including additional home/ED medications, medical history, risk scores, other additional factors.</p>
                    </fn>
                    <fn id="acem14589-note-0006">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>200 mg is the maximum IV furosemide allowed to be given as a single dose per the American College of Cardiology's recommendations.<xref rid="acem14589-bib-0061" ref-type="bibr"><sup>61</sup></xref>
</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap position="float" id="acem14589-tbl-0002" content-type="TABLE">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Echocardiographic variables obtained on point‐of‐care examination at ED arrival</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">POCecho variable</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Overall, <italic toggle="yes">N</italic> = 84</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Admitted to hospital, <italic toggle="yes">n</italic> = 76</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Discharged from ED, <italic toggle="yes">n</italic> = 8</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">p‐value, admit vs. discharge</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">No 30‐day event, <italic toggle="yes">n</italic> = 68</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">≥1 event at 30 days, <italic toggle="yes">n</italic> = 16</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">p‐value, event<xref rid="acem14589-note-0009" ref-type="table-fn"><sup>a</sup></xref> vs. no event</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" colspan="8" valign="top" rowspan="1">Right heart measures</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">TAPSE (mm)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17 (13–23)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17 (13–23)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21 (17–22)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18 (14–23)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13 (12–16)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.011</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">TAPSE/RVDD ratio (mm/mm)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.73 (2.54–5.33)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.70 (2.42–5.33)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4.32 (3.57–5.29)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4.09 (3.07–5.37)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2.73 (2.13–3.94)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.035</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">TAPSE/PASP ratio (mm/mmHg)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.37 (0.29–0.56)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.35 (0.29–0.54)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.49 (0.46–0.65)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.03</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.39 (0.30–0.65)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.29 (0.26–0.37)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.011</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">PASP [RVSP] (mm Hg)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">43 (33–50)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">44 (35–51)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">36 (30–43)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">43 (33–49)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">46 (37–53)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.3</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">RV/LV diameter ratio</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.81 (0.71–0.95)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.81 (0.71–0.95)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.76 (0.65–0.92)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.81 (0.69–0.91)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.79 (0.73–1.01)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.4</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">RVOT PW Doppler acceleration time (ms)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">84 (67–104)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">84 (67–104)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">84 (75–98)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">82 (68–104)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">86 (64–101)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.6</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Pulmonary vascular resistance (Wood units)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.47 (2.43–4.90)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.47 (2.39–5.10)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.08 (2.68–3.95)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.41 (2.41–4.60)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4.20 (2.82–6.07)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.2</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">RV FAC</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.33 (0.21–0.42)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.32 (0.21–0.42)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.37 (0.32–0.54)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.14</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.34 (0.23–0.42)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.28 (0.20–0.44)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.4</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">fwRVLS</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15 (11–21)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15 (11–21)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13 (10–20)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">16 (11–21)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12 (7–15)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.034</td>
                      </tr>
                      <tr>
                        <td align="left" colspan="8" valign="top" rowspan="1">Left heart measures</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">LVEF</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">28 (19–38)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">29 (20–39)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20 (18–29)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.14</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">28 (19–36)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">34 (22–41)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.4</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">E/A ratio</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.07 (1.48–4.16)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.07 (1.48–4.16)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.08 (1.53–3.88)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2.97 (1.49–4.32)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.29 (1.51–4.10)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.8</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">E/E'</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18.5 (15.4–22.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18.7 (15.7–22.5)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">16.4 (15.2–19.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18.5 (16.0–22.3)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18.7 (13.6–22.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.6</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">E' septal</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.04 (0.03–0.06)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.04 (0.03–0.06)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.05 (0.03–0.06)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">&gt;0.9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.05 (0.03–0.06)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.04 (0.04–0.05)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.6</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">E' lateral</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.06 (0.05–0.08)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.06 (0.05–0.08)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.06 (0.05–0.08)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.06 (0.05–0.08)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.06 (0.05–0.07)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.3</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">LVGLS</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.8 (4.8–10.2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.9 (4.6–10.6)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.7 (6.0–6.9)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.9 (4.9–10.4)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.7 (4.5–9.0)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.4</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="acem14589-ntgp-0003">
                    <fn id="acem14589-note-0007">
                      <p><italic toggle="yes">Note</italic>: Fifteen echocardiographic variables were stratified by ED disposition (left) and occurrence of at least one event in the composite primary 30‐day outcome<xref rid="acem14589-note-0009" ref-type="table-fn"><sup>a</sup></xref> (right). All echocardiography measures were collected at the point of care less than 1 h after, or any time before, first initiation of an AHF treatment in the ED (positive pressure ventilation, IV loop diuresis, IV or sublingual nitroglycerin). Only TAPSE, its ratio to RVDD and PASP, and fwRVLS were associated with the primary outcome. Only the TAPSE/PASP ratio differed between dispositions, as determined by the treating EP blinded to echocardiography. Wilcoxon rank‐sum test used for unadjusted statistical comparisons.</p>
                    </fn>
                    <fn id="acem14589-note-0008">
                      <p>Abbreviations: FAC, fractional area change; fwRVLS, free‐wall right ventricular longitudinal strain; LV, left ventricle; LVEF, left ventricular ejection fraction; PASP, pulmonary artery systolic pressure; POCecho, point‐of‐care echocardiography; RVSP, right ventricular systolic pressure; PW, pulsed wave; RV, right ventricle; RVDD, right ventricular diastolic diameter; RVOT, right ventricular outflow tract; TAPSE, tricuspid annular plane systolic excursion.</p>
                    </fn>
                    <fn id="acem14589-note-0009">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>30‐day death, CPR, mechanical cardiac support, intubation, new or emergent dialysis, acute myocardial infarction, and/or coronary revascularization.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Nineteen percent of patients (<italic toggle="yes">n</italic> = 16) had one or more serious adverse AHF events in the composite primary outcome at 30 days, including three (3.6%) deaths. Experiencing the primary outcome was associated with (Table <xref rid="acem14589-tbl-0001" ref-type="table">1</xref>) total STRATIFY score and the STRATIFY components of dialysis history and sodium concentration.</p>
                <p>Among POCecho variables (Table <xref rid="acem14589-tbl-0002" ref-type="table">2</xref>), four right heart measures and no left heart measures were associated with the primary outcome: TAPSE (<italic toggle="yes">p</italic> = 0.011), TAPSE/PASP (<italic toggle="yes">p</italic> = 0.035), TAPSE/RVDD (<italic toggle="yes">p</italic> = 0.011), and fwRVLS (<italic toggle="yes">p</italic> = 0.034). There was no difference in TAPSE between admitted versus discharged patients (Table <xref rid="acem14589-tbl-0002" ref-type="table">2</xref>) to suggest unblinding of the treating EPs to the POCecho results.</p>
              </sec>
              <sec id="acem14589-sec-0022">
                <title>Category‐free reclassification</title>
                <p>TAPSE improved category‐free reclassification of events and non‐events compared to STRATIFY alone (NRI<sub>cont</sub> +0.63 [95% CI +0.08 to +1.18]), as did TAPSE/RVDD (+0.67 [+0.18 to +1.16]) and fwRVLS (+0.49 [+0.01 to +0.98]). Significant reclassification by NRI<sub>cont</sub> was not observed for other POCecho variables or any of the clinical variables of interest including past history of COPD, history of PH, new or increasing supplemental O<sub>2</sub> requirement, ED IV loop diuretic dose, ED NIPPV or intubation, ED IV nitroglycerin, or disposition decisions of ICU or discharge home (Table <xref rid="acem14589-tbl-0003" ref-type="table">3</xref>).</p>
                <table-wrap position="float" id="acem14589-tbl-0003" content-type="TABLE">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Category‐free net reclassification and receiver operating characteristic AUC for TAPSE and selected clinical comparators</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <col align="left" span="1"/>
                    <thead valign="bottom">
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Variable of Interest</th>
                        <th align="left" rowspan="2" style="border-bottom:solid 1px #000000" valign="bottom" colspan="1">Category‐free net reclassification index (NRI<sub>cont</sub>) [95% CI]</th>
                        <th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">AUROC (validation/bias‐corrected)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">STRATIFY + variable of interest (full models)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Difference compared to STRATIFY score only (reduced model, AUC of 0.706)</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TAPSE (mm)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.63 [+0.08 to +1.18]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.756</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.050</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">History COPD</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.02 [−0.52 to +0.56]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.683</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.023</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">History pulmonary hypertension</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.18 [−0.30 to +0.66]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.676</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.030</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">GDMT adherence before ED</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.26 [−0.05 to +0.56]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.712</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.006</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ED arrival SBP</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.04 [−0.58 to +0.50]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.689</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.017</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Male sex</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.23 [−0.28 to +0.74]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.685</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.021</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">IV furosemide in ED</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.44 [−0.10 to +0.98]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.714</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.008</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">New or increased O<sub>2</sub> requirement in ED</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.19 [−0.33 to +0.71]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.700</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.006</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ED NIPPV or intubation</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.11 [−0.57 to +0.36]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.690</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.016</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ED IV nitro</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.21 [−0.20 to +0.62]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.697</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.009</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">ED disposition</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Discharge</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.08 [−0.20 to +0.36]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.725</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.019</td>
                      </tr>
                      <tr>
                        <td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">ICU</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">+0.22 [−0.19 to +0.64]</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.678</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">−0.028</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot id="acem14589-ntgp-0004">
                    <fn id="acem14589-note-0010">
                      <p><italic toggle="yes">Note</italic>: TAPSE improved net prediction/classification when added to the STRATIFY risk score (NRI<sub>cont</sub> CI does not cross zero).<xref rid="acem14589-note-0009" ref-type="table-fn"><sup>a</sup></xref> Overall, the risk stratification benefits added to STRATIFY by TAPSE were not observed for EP standard‐of‐care risk stratification or other observed variables. Potential confounding comorbidities and treatment differences outside of the 13 variables already captured by STRATIFY failed to match or explain the TAPSE‐related improvement in classification (all NRI<sub>cont</sub>
<italic toggle="yes">p</italic> &gt; 0.05) and prediction (smaller change in ROC AUC compared to TAPSE). Likewise, the improvement in classification and prediction observed with TAPSE was not observed in the actual disposition decisions of EPs blinded to echocardiogram results.</p>
                    </fn>
                    <fn id="acem14589-note-0011">
                      <p>Abbreviations: COPD, chronic obstructive pulmonary disease; GDMT, guideline‐directed medical therapy for heart failure; ICU, intensive care unit; NIPPV, noninvasive positive pressure ventilation; PH, pulmonary hypertension; ROC AUC, receiver operating characteristic area under the curve.</p>
                    </fn>
                    <fn id="acem14589-note-0012">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>Primary outcome of the STRATIFY score = 30‐day death, CPR, mechanical cardiac support, intubation, new or emergent dialysis, acute myocardial infarction, and/or coronary revascularization.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="acem14589-sec-0023">
                <title>Categorical reclassification and improvement in test characteristics at clinically benchmarked risk thresholds</title>
                <p>ED treatments and disposition decisions were similar between events and nonevents (Table <xref rid="acem14589-tbl-0001" ref-type="table">1</xref>). Figure <xref rid="acem14589-fig-0001" ref-type="fig">1</xref> shows the ΔSensitivity (NRI<sub>events</sub>) and ΔSpecificity (NRI<sub>nonevents</sub>) obtained when TAPSE at the a priori cutoff of ≥17 mm was added to STRATIFY. At every risk threshold less (i.e., more conservative) than the 8.3% benchmark (standard‐of‐care event rate among discharged patients), TAPSE ≥ 17 mm significantly increased specificity without changing sensitivity. At the 8% cutoff, a peak 32% (95% CI 20%–44%) of event‐free patients at 30 days would have been appropriately reclassified from high risk (i.e., by STRATIFY alone) to low risk (by STRATIFY and TAPSE ≥ 17 mm). At an even more conservative 4% predicted risk cutoff, 15% (6%–24%) of patients incorrectly classified as high risk by STRATIFY alone would have been appropriately reclassified to low risk. Figure <xref rid="acem14589-supitem-0001" ref-type="supplementary-material">S2</xref> shows categorical reclassification for all of the 15 POCecho variables side‐by‐side. TAPSE, the TAPSE/PASP and TAPSE/RVDD ratios, and fwRVLS stood out across multiple cutoffs for increasing specificity beyond STRATIFY alone without sacrificing sensitivity.</p>
                <fig position="float" fig-type="FIGURE" id="acem14589-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Change in sensitivity (NRI‐Events) and specificity (NRI‐Nonevents) when TAPSE is added to STRATIFY versus STRATIFY alone, for various thresholds of 30‐day risk for serious adverse heart failure events. When added to the STRATIFY risk score, TAPSE ≥ 17 mm increased specificity (TNR/NRI<sub>nonevents</sub>, i.e., correct identification of patients without a 30‐day event) without any significant change in sensitivity (i.e., no change in missed events) for risk thresholds benchmarked to the actual 30‐day outcome rate among discharged patients. If the use of TAPSE + STRATIFY were used conservatively (i.e., only at risk thresholds more conservative than the adverse event rate occurring under standard‐of‐care EP disposition decision making) there still would have been a significant increase in the number of low‐risk patients identified without significant change in missed cases. AMI, acute myocardial infarction; CABG, coronary artery bypass graft; NRI, net reclassification index; MCS, mechanical cardiac support; PCI, percutaneous coronary intervention; TNR, true‐negative rate = NRI<sub>nonevents</sub> = Δspecificity; TPR, true‐positive rate = NRI<sub>events</sub> = Δ sensitivity; TAPSE, tricuspid plane systolic excursion.</p>
                  </caption>
                  <graphic xlink:href="ACEM-29-1306-g001" position="anchor" id="jats-graphic-1"/>
                </fig>
              </sec>
              <sec id="acem14589-sec-0024">
                <title>Echocardiographic measure importance</title>
                <p>Figure <xref rid="acem14589-fig-0002" ref-type="fig">2</xref> presents variable importance for each POCecho measure in predicting the primary outcome. TAPSE was the most important POCecho measure. Despite being only a single variable, TAPSE was nevertheless almost three‐fourths as important on its own as the entire 13‐variable STRATIFY score. The five most important POCecho variables were right heart measures. E/e' was the most important left heart measure, followed by LVEF and LVGLS.</p>
                <fig position="float" fig-type="FIGURE" id="acem14589-fig-0002">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Relative importance of echocardiographic variables for predicting 30‐day serious adverse heart failure events in conjunction with the STRATIFY decision instrument importance on random forest of each echocardiography variable in predicting the primary outcome of the STRATIFY decision score* after adjusting for the STRATIFY score itself. Eight of the 10 variables which added the most risk prediction to STRATIFY were right heart measures. TAPSE, the primary measure of interest, was the most important echocardiography variable. As a single variable, TAPSE was &gt;70% as important as the entire 13 variable STRATIFY score in predicting STRATIFY's outcome. *30‐day death, CPR, mechanical cardiac support, intubation, new or emergent dialysis, acute myocardial infarction, and/or coronary revascularization. FAC, RV fractional area change; fwRVLS, free‐wall RV longitudinal strain; LV, left ventricle; LVEF, left ventricular ejection fraction; LVGLS, LV global longitudinal strain; PASP, pulmonary artery systolic pressure; PVR, pulmonary vascular resistance; PW, pulsed wave; RV, right ventricle; RVDD, right ventricular diastolic diameter; RVOT, right ventricular outflow tract; TAPSE, tricuspid annular plane systolic excursion.</p>
                  </caption>
                  <graphic xlink:href="ACEM-29-1306-g002" position="anchor" id="jats-graphic-3"/>
                </fig>
              </sec>
              <sec id="acem14589-sec-0025">
                <title>Echo measures adjusted for <styled-content style="fixed-case" toggle="no">STRATIFY</styled-content>
</title>
                <p>Figure <xref rid="acem14589-supitem-0001" ref-type="supplementary-material">S1</xref> presents ORs and the STRATIFY aOR’s for each POCecho measure and the primary outcome, presented as continuous (OR/aOR per change in IQR) and binary variables. TAPSE had an aOR of 0.32 (95% CI 0.12–0.87) as a continuous variable and 0.24 (0.06–0.91) at the ≥17 mm a priori cutoff. Internally validated (bias‐corrected) AUROC was 0.756 for TAPSE plus STRATIFY versus 0.706 in STRATIFY alone.</p>
                <p>Four additional right heart variables were associated with the outcome after adjusting for STRATIFY: TAPSE/RVDD ratio (aOR 0.35 [0.13–0.94]), TAPSE/PASP ratio (0.38 [0.15–0.96]), RV‐FAC (0.41 [0.17–0.94]), and fwRVLS (0.31 [0.11–0.9]). RV‐LV ratio &lt; 1 (but not as a continuous variable) was also associated with the primary outcome after adjustment (0.24 [0.06–0.78]). No left heart measures were associated with the primary outcome.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="acem14589-sec-0026">
              <title>DISCUSSION</title>
              <p>In this study, we prospectively validated pilot data suggesting that TAPSE improves risk stratification of AHF patients in the ED for clinically relevant adverse AHF events. We highlight four major findings. First, TAPSE improved risk classification beyond the previously validated<xref rid="acem14589-bib-0011" ref-type="bibr"><sup>11</sup></xref> and ACEP‐endorsed<xref rid="acem14589-bib-0007" ref-type="bibr"><sup>7</sup></xref> STRATIFY CDI by multiple measures: NRI<sub>cont</sub>, aOR, and the ability to identify low‐risk AHF patients (i.e., higher NRI<sub>nonevent</sub>/ΔSpecificity) without increasing “missed” high‐risk patients (i.e., no change in NRI<sub>event</sub>/ΔSensitivity). Second, TAPSE and other right‐heart measures showed greater importance (Figure <xref rid="acem14589-fig-0002" ref-type="fig">2</xref>), effect size on STRATIFY adjusted odds (Figure <xref rid="acem14589-supitem-0001" ref-type="supplementary-material">S1</xref>), reclassification (Table <xref rid="acem14589-tbl-0003" ref-type="table">3</xref>), and prediction of low‐risk (Figures <xref rid="acem14589-fig-0001" ref-type="fig">1</xref> and <xref rid="acem14589-supitem-0001" ref-type="supplementary-material">S2</xref>) than left heart measures. Third, TAPSE improved classification even where other clinical factors not in the STRATIFY score did not (e.g., ED disposition, COPD, PH history, supplemental oxygen requirement, IV diuretic dose, NIPPV, etc.; Table <xref rid="acem14589-tbl-0003" ref-type="table">3</xref>). Fourth, improved identification of low‐risk patients with TAPSE (Figure <xref rid="acem14589-fig-0001" ref-type="fig">1</xref>) was observed even when benchmarked to ensure that TAPSE miss rates were more conservative than real EPs' actual disposition decisions when blinded to the POCecho results.</p>
              <p>This is the first and most comprehensive prospective report on the utility of POCecho to aid in AHF risk stratification in the ED. Sax et al.<xref rid="acem14589-bib-0062" ref-type="bibr"><sup>62</sup></xref> recently described the prognostic utility of historical LVEF in AHF in a large retrospective study, which we believe to be one of the few reports describing any echocardiographic variable in ED risk‐stratification, whether POC or not. In addition to REED‐AHF, other POCecho studies such as one by Favot et al.<xref rid="acem14589-bib-0063" ref-type="bibr"><sup>63</sup></xref> and a previously reported secondary aim of REED‐AHF<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> have described the utility of longitudinal changes from ED arrival to inpatient timepoints, including with TAPSE.<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> Nevertheless, among the six or more described CDIs for ED risk stratification of AHF, none incorporate echocardiographic variables.<xref rid="acem14589-bib-0064" ref-type="bibr"><sup>64</sup></xref> This is despite copious literature describing the utility of right heart echocardiography measures for heart failure risk prediction outside of the ED setting.<xref rid="acem14589-bib-0006" ref-type="bibr"><sup>6</sup></xref>, <xref rid="acem14589-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="acem14589-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="acem14589-bib-0020" ref-type="bibr"><sup>20</sup></xref>, <xref rid="acem14589-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="acem14589-bib-0022" ref-type="bibr"><sup>22</sup></xref>, <xref rid="acem14589-bib-0023" ref-type="bibr"><sup>23</sup></xref>, <xref rid="acem14589-bib-0024" ref-type="bibr"><sup>24</sup></xref>, <xref rid="acem14589-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="acem14589-bib-0026" ref-type="bibr"><sup>26</sup></xref>, <xref rid="acem14589-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="acem14589-bib-0028" ref-type="bibr"><sup>28</sup></xref>, <xref rid="acem14589-bib-0029" ref-type="bibr"><sup>29</sup></xref>, <xref rid="acem14589-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="acem14589-bib-0031" ref-type="bibr"><sup>31</sup></xref>, <xref rid="acem14589-bib-0032" ref-type="bibr"><sup>32</sup></xref>, <xref rid="acem14589-bib-0033" ref-type="bibr"><sup>33</sup></xref>, <xref rid="acem14589-bib-0034" ref-type="bibr"><sup>34</sup></xref>, <xref rid="acem14589-bib-0035" ref-type="bibr"><sup>35</sup></xref>, <xref rid="acem14589-bib-0036" ref-type="bibr"><sup>36</sup></xref>, <xref rid="acem14589-bib-0037" ref-type="bibr"><sup>37</sup></xref>, <xref rid="acem14589-bib-0039" ref-type="bibr"><sup>39</sup></xref>, <xref rid="acem14589-bib-0040" ref-type="bibr"><sup>40</sup></xref>, <xref rid="acem14589-bib-0041" ref-type="bibr"><sup>41</sup></xref>, <xref rid="acem14589-bib-0042" ref-type="bibr"><sup>42</sup></xref>, <xref rid="acem14589-bib-0043" ref-type="bibr"><sup>43</sup></xref>, <xref rid="acem14589-bib-0044" ref-type="bibr"><sup>44</sup></xref>, <xref rid="acem14589-bib-0045" ref-type="bibr"><sup>45</sup></xref>, <xref rid="acem14589-bib-0046" ref-type="bibr"><sup>46</sup></xref>
</p>
              <p>That echocardiography has so far been excluded from AHF risk stratification in the ED is surprising. Namely, being able to visualize the main organ affected in AHF to assess severity of presentation has clear face validity. Moreover, POCecho measures including TAPSE have been used with reliability and utility by EPs for risk stratification of other conditions like pulmonary embolism (PE).<xref rid="acem14589-bib-0047" ref-type="bibr"><sup>47</sup></xref>, <xref rid="acem14589-bib-0048" ref-type="bibr"><sup>48</sup></xref>, <xref rid="acem14589-bib-0050" ref-type="bibr"><sup>50</sup></xref> Nevertheless, prior literature on the appropriate use of POC ultrasound in AHF for ED patients is highly limited to diagnosis and assessment of volume status<xref rid="acem14589-bib-0065" ref-type="bibr"><sup>65</sup></xref> but not risk prediction. LUS, but not POCecho, has also been described for the latter purpose including the recent BLUSHED‐AHF trial<xref rid="acem14589-bib-0066" ref-type="bibr"><sup>66</sup></xref> and the previous publication from REED‐AHF.<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> Concurrently, even the three strongest CDIs<xref rid="acem14589-bib-0008" ref-type="bibr"><sup>8</sup></xref>, <xref rid="acem14589-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="acem14589-bib-0010" ref-type="bibr"><sup>10</sup></xref> described for ED risk stratification, two of which have been documented to outperform EP gestalt,<xref rid="acem14589-bib-0009" ref-type="bibr"><sup>9</sup></xref>, <xref rid="acem14589-bib-0010" ref-type="bibr"><sup>10</sup></xref> are viewed by ACEP as potentially useful but nevertheless not strong enough to guide disposition on their own.<xref rid="acem14589-bib-0007" ref-type="bibr"><sup>7</sup></xref> With the existence of at least six different ED CDIs for AHF risk prediction utilizing a large overlap of the same clinical variables,<xref rid="acem14589-bib-0064" ref-type="bibr"><sup>64</sup></xref> echocardiographic variables are among the last remaining “new” (i.e., previously unused) markers to include in ED risk stratification and potentially improve upon the status quo.</p>
              <p>Our study has several strengths. First, we prospectively tested our primary hypothesis and found TAPSE to be useful not only as a continuous variable but also at the binary cutoff we specified a priori from prior research.<xref rid="acem14589-bib-0017" ref-type="bibr"><sup>17</sup></xref> Due to a large effect size, we were able to detect a difference even with a slightly abbreviated sample size (on account of the COVID‐19 pandemic) compared to our prespecified power analysis. TAPSE ≥ 17 mm, after adjusting for STRATIFY, predicted a further fourfold reduction in odds of adverse events which was greater than anticipated. Second, we used rigorous methods<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> to adjudicate AHF diagnosis and outcomes, including multiple blinded raters and multiple redundant information sources for follow‐up, and included follow‐up methods designed to detect outcomes occurring outside our institutions (e.g., HIE data and telephone follow‐up). Third, ED ultrasound examinations were performed at the point of care primarily by attending physician and resident investigators (NH, JL) without advanced fellowship training in POCUS, but measurements were nevertheless shown to have high ICC with blinded expert testamurs of the NBE (MF, RE) and one additional blinded offline reviewer (LG). This included measurements expected to be the most challenging for EPs, such as fwRVLS. Every patient screened in whom a POCecho was attempted had adequate images to measure TAPSE, compared to two patients in whom LVEF (a basic POCecho requirement for all EM residents) could not be obtained. Fourth, we measured a broad swath of echocardiographic variables far earlier in the treatment course than any prior studies of POC or formal echocardiography, while enrolling a broad mix of acuity. As shown in a previously published report from REED‐AHF,<xref rid="acem14589-bib-0038" ref-type="bibr"><sup>38</sup></xref> measures of RVD like TAPSE and those of PH like PASP changed dramatically between the initial ED echocardiograms and even 24 h later. The next earliest enrolling AHF study evaluating right heart function for risk prediction<xref rid="acem14589-bib-0025" ref-type="bibr"><sup>25</sup></xref> included patients hours after hospital admission, meaning that we were able to observe RVD and PH that may otherwise have been missed. Finally, we used a novel approach with face validity to address a key risk of bias affecting all studies of ED risk prediction/stratification in AHF: i.e., the vast majority of AHF patients are admitted to the hospital, and admission could change risk compared to discharge. We approached this problem by tying our most important measures (ΔSensitivity [NRI<sub>events</sub>] and ΔSpecificity [NRI<sub>nonevents</sub>]) to risk thresholds more conservative than the actual outcome rates experienced by patients whom POCecho‐blinded EPs chose to discharge. This was done to acknowledge the status quo: conservative disposition practices resulting in admission for 80%–90% of patients and &lt; 50% of patients receiving an intervention requiring hospital admission (Table <xref rid="acem14589-tbl-0001" ref-type="table">1</xref>—new oxygen requirement, PPV/intubation, IV nitro, and/or higher total IV diuretic dose than allowed to be given as a single dose by ACC guidelines<xref rid="acem14589-bib-0061" ref-type="bibr"><sup>61</sup></xref>). Concurrently, rather than seeking primarily to answer broad but less clinically actionable questions about prediction across the total spectrum of risk<xref rid="acem14589-bib-0060" ref-type="bibr"><sup>60</sup></xref> (e.g., whether TAPSE improves AUROC), we asked whether TAPSE could improve identification of patients on the low‐risk end of the spectrum whom clinicians might then be able to consider for outpatient therapy (discharge or observation). This approach was specifically designed to match the critical need of an unnecessarily high admission rate in the United States (possibly by 50% or more<xref rid="acem14589-bib-0008" ref-type="bibr"><sup>8</sup></xref>) with a clinically actionable goal: if an ED patient has no absolute indications for inpatient status (e.g., supplemental oxygen), adding TAPSE ≥ 17 mm to a STRATIFY risk score can increase the odds of appropriately identifying individuals with lower‐than‐average rates of adverse 30‐day events to help facilitate safe outpatient management in an otherwise high‐risk population.</p>
            </sec>
            <sec id="acem14589-sec-0027">
              <title>LIMITATIONS</title>
              <p>Our study also has several limitations. First, despite the methods described to address the bias of high admission rates in AHF risk stratification literature, we cannot eliminate this bias entirely. The only way to do this completely would be to enforce mandatory EP disposition decisions in a randomized trial based on TAPSE and STRATIFY.</p>
              <p>Second, our study was powered to detect whether TAPSE ≥ 17 mm could add predictive utility to the existing STRATIFY score, which is not the same as if we had refit a new model including all 13 individual variables in STRATIFY plus TAPSE (i.e. as the 14th). At the outcome rates observed, we would have required more than eight times the number of patients enrolled to have enough events to prevent overfitting on logistic regression fitting an entirely new CDI with as many variables<xref rid="acem14589-bib-0013" ref-type="bibr"><sup>13</sup></xref> as STRATIFY. Given the feasibility of obtaining POCechos early in the course and the novel nature of our hypothesis among ED studies, this was not seen as feasible and therefore not the goal of REED‐AHF. Based on our current results a future study of that scope may now be justified, to derive a de novo CDI including prospectively collected TAPSE and/or other POCecho markers alongside traditional clinical variables.</p>
              <p>Third, we had slightly less than 10 events per variable when considering both the STRATIFY score and a POCecho variable (i.e., eight events per variable). Our sample size was slightly abridged due to the COVID‐19 pandemic as discussed, and prior research has shown that as low as five events per variable is usually sufficient to prevent overfitting.<xref rid="acem14589-bib-0067" ref-type="bibr"><sup>67</sup></xref> Moreover, the STRATIFY score actually performed better by AUROC in our sample (0.706 after bootstrap correction for bias/optimism) than in its original derivation,<xref rid="acem14589-bib-0008" ref-type="bibr"><sup>8</sup></xref> making it doubtful that our results are due to poor performance of our chosen confounder (STRATIFY) in the 16 events observed. Likewise, predicted bias/optimism in the TAPSE‐adjusted model<xref rid="acem14589-bib-0059" ref-type="bibr"><sup>59</sup></xref> was overall low (AUROC optimism 0.026, with an observed AUROC 0.796 vs. 0.756 bias‐corrected), suggesting a lower chance that a higher event count would have led to much worse performance in an external sample or if enrollment targets had been met. Nevertheless, we cannot say for certain how completion of the original enrollment target would have changed results, which in turn makes our results more hypothesis generating than overtly practice changing. Ultimately, as mentioned, a larger study than even our initial enrollment target will be needed to derive and then validate direct incorporation of TAPSE into a de novo CDI. A future study to externally validate our results here is also warranted, especially in view of this limitation.</p>
              <p>Fourth, we did not directly test learning curves for TAPSE in EP hands (e.g., compared to current requirements for EM residency in POCecho), although ICC to experts was high and feasibility of EP‐performed TAPSE for risk stratification has been demonstrated in prior studies of PE.<xref rid="acem14589-bib-0047" ref-type="bibr"><sup>47</sup></xref>, <xref rid="acem14589-bib-0048" ref-type="bibr"><sup>48</sup></xref> No patients were excluded from the current study for images insufficient to grade TAPSE, but a future study to directly describe learning curves and pedagogy in EM learners would be helpful.</p>
              <p>Fifth, the study was not designed to compare POCecho variables head to head, and the abridged enrollment likely decreased this power even further. Given this, we cannot say that other echocardiography variables such as LVEF and mitral inflow parameters are of low utility, but rather only that we had low power to detect a difference among various echocardiography parameters. Nevertheless, other measures all had lower variable importance (Figure <xref rid="acem14589-fig-0002" ref-type="fig">2</xref>) and aOR effect size (Figure <xref rid="acem14589-supitem-0001" ref-type="supplementary-material">S1</xref>) than TAPSE.</p>
              <p>Sixth, our population is medically underserved, predominantly non‐White, coming from only two hospitals (DRH, SGH) and two institutions (Wayne State and Michigan State University College of Osteopathic Medicine). Generalizability to different populations is therefore uncertain.</p>
            </sec>
            <sec id="acem14589-sec-0028">
              <title>CONCLUSIONS</title>
              <p>Tricuspid annulus plane systolic excursion (TAPSE) significantly improved risk stratification compared to the validated STRATIFY clinical decision instrument. Most critically, TAPSE appears to improve detection of low‐risk acute heart failure, even among patients misclassified as high risk. TAPSE, the TAPSE/PASP ratio, the TAPSE/RVDD ratio, and fwRVLS may all help increase the identification of low‐risk acute heart failure patients in the ED who could be considered for outpatient treatment rather than hospital admission. Our hypothesis‐generating results support a need to further define and evaluate point‐of‐care echocardiography's role in acute heart failure risk stratification. Future studies should investigate the incorporation of point‐of‐care echocardiography variables, and particularly right‐heart measures, into acute heart failure clinical decision instruments given their demonstrated potential here, the face validity for acute heart failure risk‐stratification, and the status of echocardiography as one of the few accessible clinical parameters not already used to risk‐stratify acute heart failure in the emergency department.</p>
            </sec>
            <sec id="acem14589-sec-0029">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p>Study concept and design: Nicholas E. Harrison, Robert Ehrman, Mark J. Favot, Phillip Levy, Aiden Abidov. Acquisition of the data: Nicholas E. Harrison, Laura Gowland, Jacob Lenning, Sarah Henry, Sushane Gupta, Robert Ehrman, Mark J. Favot. Analysis and Interpretation of the data: Nicholas E. Harrison, Jacob Lenning, Laura Gowland, Robert Ehrman, Mark J. Favot. Drafting of the manuscript: Nicholas E. Harrison. Critical revision of the manuscript for important intellectual content: all authors. Statistical expertise: Nicholas E. Harrison, Robert Ehrman. Acquisition of funding: Nicholas E. Harrison, Robert Ehrman, Mark J. Favot.</p>
            </sec>
            <sec id="acem14589-sec-0031">
              <title>FUNDING INFORMATION</title>
              <p>Funded by the Blue Cross Blue Shield of Michigan Foundation (BCBSMF) Investigator‐Initiated Grant Program. This publication was made possible with support from Grant Numbers, KL2TR002530 (Sheri L. Robb, PI), and UL1TR002529 (Sharon M. Moe and Sarah E. Wiehe, co‐PIs) from the National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award.</p>
            </sec>
            <sec sec-type="COI-statement" id="acem14589-sec-0032">
              <title>CONFLICT OF INTEREST</title>
              <p>JL, SH, SG, and LG report no conflicts of interest. NH's first institution, Wayne State University, has received grant money to conduct investigator‐initiated research conceived and written by NH from BCBSMF. NH and their second institution, Indiana University, have received grant money to conduct investigator‐initiated research conceived and written by NH from the Doris Duke Foundation and the National Institutes of Health (5KL2TR002530‐05). NH's second institution, Indiana University, has received grant money for industry‐initiated research from Abbott Laboratories and Roche Diagnostics. NH has received funding from Vave Health Inc. for consulting. RE has received grant money to conduct investigator‐initiated research from the National Institutes of Health conceived and written by Dr. Peter Pang at Indiana University (1R34HL136986‐01) and investigator‐initiated research conceived and written by NH from BCBSMF. RE has received funding from UltraSight for consulting. MF has received grant money to conduct investigator‐initiated research conceived and written by NH from BCBSMF. MF serves on the medical advisory board for Echonous Inc. and has received stock options from Echonous Inc. AA has received grant money to conduct investigator‐initiated research conceived and written by NH from BCBSMF. PL has received funding for consulting from Apex Innovations, AstraZeneca, BMS, Mespere, Novartis, Cardionomics, Baim Institute, Ortho Clinical Diagnostics, Roche Diagnostics, Siemens, Hospital Quality Foundation. PL and their institution have received investigator‐initiated research support from American Heart Association, Beckman Coulter, Agency for Healthcare Research and Quality (AHRQ), BCBSMF, Emergency Medicine Foundation, Edwards Lifesciences, CardioSounds, Michigan Department of Health and Human Services, Michigan Health Endowment Fund, Patient Centered Outcome Research Institute, and the National Institutes of Health NIH. PL is a member of the ACC's National Cardiovascular Data Registry Oversight Committee.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="acem14589-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p>
Figure S1
</p>
                  <p>
Figure S2
</p>
                </caption>
                <media xlink:href="ACEM-29-1306-s001.zip">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="acem14589-sec-0030">
              <title>ACKNOWLEDGMENTS</title>
              <p>The authors thank Blue Cross Blue Shield of Michigan Foundation (BCBSMF) for grant support.</p>
            </ack>
            <ref-list content-type="cited-references" id="acem14589-bibl-0001">
              <title>REFERENCES</title>
              <ref id="acem14589-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0001"><string-name><surname>Benjamin</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Muntner</surname><given-names>P</given-names></string-name>, <string-name><surname>Alonso</surname><given-names>A</given-names></string-name>, et al. <article-title>Heart disease and stroke Statistics‐2019 update: a report from the American Heart Association</article-title>. <source>Circulation</source>. <year>2019</year>;<volume>139</volume>(<issue>10</issue>):<fpage>e56</fpage>‐<lpage>e528</lpage>.<pub-id pub-id-type="pmid">30700139</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0002"><string-name><surname>Martindale</surname><given-names>JL</given-names></string-name>, <string-name><surname>Wakai</surname><given-names>A</given-names></string-name>, <string-name><surname>Collins</surname><given-names>SP</given-names></string-name>, et al. <article-title>Diagnosing Acute heart failure in the emergency department: a systematic review and meta‐analysis</article-title>. <source>Acad Emerg Med</source>. <year>2016</year>;<volume>23</volume>(<issue>3</issue>):<fpage>223</fpage>‐<lpage>242</lpage>.<pub-id pub-id-type="pmid">26910112</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0003"><string-name><surname>Butler</surname><given-names>J</given-names></string-name>, <string-name><surname>Hanumanthu</surname><given-names>S</given-names></string-name>, <string-name><surname>Chomsky</surname><given-names>D</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>JR</given-names></string-name>. <article-title>Frequency of low‐risk hospital admissions for heart failure</article-title>. <source>Am J Cardiol</source>. <year>1998</year>;<volume>81</volume>(<issue>1</issue>):<fpage>41</fpage>‐<lpage>44</lpage>.<pub-id pub-id-type="pmid">9462604</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0004"><string-name><surname>Fish‐Trotter</surname><given-names>H</given-names></string-name>, <string-name><surname>Collins</surname><given-names>SP</given-names></string-name>, <string-name><surname>Danagoulian</surname><given-names>S</given-names></string-name>, et al. <article-title>Design and rationale of a randomized trial: using short stay units instead of routine admission to improve patient centered health outcomes for acute heart failure patients (SSU‐AHF)</article-title>. <source>Contemp Clin Trials</source>. <year>2018</year>;<volume>72</volume>:<fpage>137</fpage>‐<lpage>145</lpage>.<pub-id pub-id-type="pmid">30125731</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0005"><string-name><surname>Collins</surname><given-names>SP</given-names></string-name>, <string-name><surname>Storrow</surname><given-names>AB</given-names></string-name>, <string-name><surname>Levy</surname><given-names>PD</given-names></string-name>, et al. <article-title>Early Management of Patients with Acute Heart Failure: state of the art and future directions‐a consensus document from the SAEM/HFSA Acute heart failure working group</article-title>. <source>Acad Emerg Med</source>. <year>2015</year>;<volume>22</volume>(<issue>1</issue>):<fpage>94</fpage>‐<lpage>112</lpage>.<pub-id pub-id-type="pmid">25423908</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0006"><string-name><surname>Harrison</surname><given-names>NE</given-names></string-name>, <string-name><surname>Meram</surname><given-names>S</given-names></string-name>, <string-name><surname>Li</surname><given-names>X</given-names></string-name>, et al. <article-title>Hemodynamic profiles by non‐invasive monitoring of cardiac index and vascular tone in acute heart failure patients in the emergency department: external validation and clinical outcomes</article-title>. <source>PloS One</source>. <year>2022</year>;<volume>17</volume>(<issue>3</issue>):<elocation-id>e0265895</elocation-id>.<pub-id pub-id-type="pmid">35358231</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0007"><string-name><surname>Silvers</surname><given-names>S</given-names></string-name>, <string-name><surname>Gemme</surname><given-names>SR</given-names></string-name>, <string-name><surname>Hickey</surname><given-names>S</given-names></string-name>, <string-name><surname>Mattu</surname><given-names>A</given-names></string-name>, <string-name><surname>Haukoos</surname><given-names>JS</given-names></string-name>, <string-name><surname>Wolf</surname><given-names>SJ</given-names></string-name>. <article-title>Clinical policy: critical issues in the evaluation and Management of Adult Patients Presenting to the emergency department with Acute heart failure syndromes</article-title>. <source>Ann Emerg Med</source>. <year>2022</year>;<fpage>78</fpage>.<pub-id pub-id-type="pmid">34949408</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0008"><string-name><surname>Collins</surname><given-names>SP</given-names></string-name>, <string-name><surname>Jenkins</surname><given-names>CA</given-names></string-name>, <string-name><surname>Harrell</surname><given-names>FE</given-names><suffix>Jr</suffix></string-name>, et al. <article-title>Identification of emergency department patients with Acute heart failure at low risk for 30‐day adverse events: the STRATIFY decision tool</article-title>. <source>JACC Heart Fail</source>. <year>2015</year>;<volume>3</volume>(<issue>10</issue>):<fpage>737</fpage>‐<lpage>747</lpage>.<pub-id pub-id-type="pmid">26449993</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0009"><string-name><surname>Lee</surname><given-names>DS</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JS</given-names></string-name>, <string-name><surname>Schull</surname><given-names>MJ</given-names></string-name>, et al. <article-title>Prospective validation of the emergency heart failure mortality risk grade for Acute heart failure</article-title>. <source>Circulation</source>. <year>2019</year>;<volume>139</volume>(<issue>9</issue>):<fpage>1146</fpage>‐<lpage>1156</lpage>.<pub-id pub-id-type="pmid">30586748</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0010"><string-name><surname>Stiell</surname><given-names>IG</given-names></string-name>, <string-name><surname>Perry</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Clement</surname><given-names>CM</given-names></string-name>, et al. <article-title>Prospective and explicit clinical validation of the Ottawa heart failure risk scale, with and without use of quantitative NT‐proBNP</article-title>. <source>Acad Emerg Med</source>. <year>2017</year>;<volume>24</volume>(<issue>3</issue>):<fpage>316</fpage>‐<lpage>327</lpage>.<pub-id pub-id-type="pmid">27976497</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0011"><string-name><surname>Sax</surname><given-names>DR</given-names></string-name>, <string-name><surname>Mark</surname><given-names>DG</given-names></string-name>, <string-name><surname>Huang</surname><given-names>J</given-names></string-name>, et al. <article-title>Use of machine learning to develop a risk‐stratification tool for emergency department patients with Acute heart failure</article-title>. <source>Ann Emerg Med</source>. <year>2021</year>;<volume>77</volume>(<issue>2</issue>):<fpage>237</fpage>‐<lpage>248</lpage>.<pub-id pub-id-type="pmid">33349492</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0012"><string-name><surname>Garg</surname><given-names>N</given-names></string-name>, <string-name><surname>Pekmezaris</surname><given-names>R</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>G</given-names></string-name>, et al. <article-title>Performance of emergency heart failure mortality risk grade in the emergency department</article-title>. <source>West J Emerg Med</source>. <year>2021</year>;<volume>22</volume>(<issue>3</issue>):<fpage>672</fpage>‐<lpage>677</lpage>.<pub-id pub-id-type="pmid">34125045</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0013"><string-name><surname>Stiell</surname><given-names>IG</given-names></string-name>, <string-name><surname>Clement</surname><given-names>CM</given-names></string-name>, <string-name><surname>Brison</surname><given-names>RJ</given-names></string-name>, et al. <article-title>A risk scoring system to identify emergency department patients with heart failure at high risk for serious adverse events</article-title>. <source>Acad Emerg Med</source>. <year>2013</year>;<volume>20</volume>(<issue>1</issue>):<fpage>17</fpage>‐<lpage>26</lpage>.<pub-id pub-id-type="pmid">23570474</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0014"><string-name><surname>Sax</surname><given-names>DR</given-names></string-name>, <string-name><surname>Mark</surname><given-names>DG</given-names></string-name>, <string-name><surname>Hsia</surname><given-names>RY</given-names></string-name>, <string-name><surname>Tan</surname><given-names>TC</given-names></string-name>, <string-name><surname>Tabada</surname><given-names>GH</given-names></string-name>, <string-name><surname>Go</surname><given-names>AS</given-names></string-name>. <article-title>Short‐term outcomes and factors associated with adverse events among adults discharged from the emergency department after treatment for Acute heart failure</article-title>. <source>Circ Heart Fail</source>. <year>2017</year>;<volume>10</volume>(<issue>12</issue>):<elocation-id>e004144</elocation-id>.<pub-id pub-id-type="pmid">29237710</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0015"><string-name><surname>McCausland</surname><given-names>JB</given-names></string-name>, <string-name><surname>Machi</surname><given-names>MS</given-names></string-name>, <string-name><surname>Yealy</surname><given-names>DM</given-names></string-name>. <article-title>Emergency physicians' risk attitudes in acute decompensated heart failure patients</article-title>. <source>Acad Emerg Med</source>. <year>2010</year>;<volume>17</volume>(<issue>1</issue>):<fpage>108</fpage>‐<lpage>110</lpage>.<pub-id pub-id-type="pmid">20078443</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0016"><string-name><surname>Collins</surname><given-names>SP</given-names></string-name>, <string-name><surname>Levy</surname><given-names>PD</given-names></string-name>, <string-name><surname>Fermann</surname><given-names>GJ</given-names></string-name>, et al. <article-title>What's next for Acute heart failure research?</article-title><source>Acad Emerg Med</source>. <year>2018</year>;<volume>25</volume>(<issue>1</issue>):<fpage>85</fpage>‐<lpage>93</lpage>.<pub-id pub-id-type="pmid">28990334</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0017"><string-name><surname>Harrison</surname><given-names>N</given-names></string-name>, <string-name><surname>Favot</surname><given-names>M</given-names></string-name>, <string-name><surname>Ehrman</surname><given-names>R</given-names></string-name>, <string-name><surname>Levy</surname><given-names>P</given-names></string-name>. <article-title>Right ventricular dysfunction on arrival predicts Acute heart failure severity and recidivism</article-title>. <source>Acad Emerg Med</source>. <year>2019</year>;<volume>26</volume>(<issue>S1</issue>):<fpage>S217</fpage>.</mixed-citation>
              </ref>
              <ref id="acem14589-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0018"><string-name><surname>Aronson</surname><given-names>D</given-names></string-name>, <string-name><surname>Darawsha</surname><given-names>W</given-names></string-name>, <string-name><surname>Atamna</surname><given-names>A</given-names></string-name>, et al. <article-title>Pulmonary hypertension, right ventricular function, and clinical outcome in acute decompensated heart failure</article-title>. <source>J Card Fail</source>. <year>2013</year>;<volume>19</volume>(<issue>10</issue>):<fpage>665</fpage>‐<lpage>671</lpage>.<pub-id pub-id-type="pmid">24125104</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0019"><string-name><surname>Gorter</surname><given-names>TM</given-names></string-name>, <string-name><surname>Hoendermis</surname><given-names>ES</given-names></string-name>, <string-name><surname>van Veldhuisen</surname><given-names>DJ</given-names></string-name>, et al. <article-title>Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta‐analysis</article-title>. <source>Eur J Heart Fail</source>. <year>2016</year>;<volume>18</volume>(<issue>12</issue>):<fpage>1472</fpage>‐<lpage>1487</lpage>.<pub-id pub-id-type="pmid">27650220</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0020"><string-name><surname>Guazzi</surname><given-names>M</given-names></string-name>, <string-name><surname>Dixon</surname><given-names>D</given-names></string-name>, <string-name><surname>Labate</surname><given-names>V</given-names></string-name>, et al. <article-title>RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes</article-title>. <source>JACC Cardiovasc Imaging</source>. <year>2017</year>;<volume>10</volume>(<issue>10 Pt B</issue>):<fpage>1211</fpage>‐<lpage>1221</lpage>.<pub-id pub-id-type="pmid">28412423</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0021"><string-name><surname>Meluzin</surname><given-names>J</given-names></string-name>, <string-name><surname>Spinarova</surname><given-names>L</given-names></string-name>, <string-name><surname>Hude</surname><given-names>P</given-names></string-name>, et al. <article-title>Combined right ventricular systolic and diastolic dysfunction represents a strong determinant of poor prognosis in patients with symptomatic heart failure</article-title>. <source>Int J Cardiol</source>. <year>2005</year>;<volume>105</volume>(<issue>2</issue>):<fpage>164</fpage>‐<lpage>173</lpage>.<pub-id pub-id-type="pmid">16243108</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0022"><string-name><surname>Mendes Fde</surname><given-names>S</given-names></string-name>, <string-name><surname>Atié</surname><given-names>J</given-names></string-name>, <string-name><surname>Garcia</surname><given-names>MI</given-names></string-name>, et al. <article-title>Atrial fibrillation in decompensated heart failure: associated factors and in‐hospital outcome</article-title>. <source>Arq Bras Cardiol</source>. <year>2014</year>;<volume>103</volume>(<issue>4</issue>):<fpage>315</fpage>‐<lpage>322</lpage>.<pub-id pub-id-type="pmid">25352505</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0023"><string-name><surname>Mukherjee</surname><given-names>M</given-names></string-name>, <string-name><surname>Sharma</surname><given-names>K</given-names></string-name>, <string-name><surname>Madrazo</surname><given-names>JA</given-names></string-name>, <string-name><surname>Tedford</surname><given-names>RJ</given-names></string-name>, <string-name><surname>Russell</surname><given-names>SD</given-names></string-name>, <string-name><surname>Hays</surname><given-names>AG</given-names></string-name>. <article-title>Right‐sided cardiac dysfunction in heart failure with preserved ejection fraction and worsening renal function</article-title>. <source>Am J Cardiol</source>. <year>2017</year>;<volume>120</volume>(<issue>2</issue>):<fpage>274</fpage>‐<lpage>278</lpage>.<pub-id pub-id-type="pmid">28528661</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0024"><string-name><surname>Verhaert</surname><given-names>D</given-names></string-name>, <string-name><surname>Mullens</surname><given-names>W</given-names></string-name>, <string-name><surname>Borowski</surname><given-names>A</given-names></string-name>, et al. <article-title>Right ventricular response to intensive medical therapy in advanced decompensated heart failure</article-title>. <source>Circ Heart Fail</source>. <year>2010</year>;<volume>3</volume>(<issue>3</issue>):<fpage>340</fpage>‐<lpage>346</lpage>.<pub-id pub-id-type="pmid">20176715</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0025"><string-name><surname>Palazzuoli</surname><given-names>A</given-names></string-name>, <string-name><surname>Ruocco</surname><given-names>G</given-names></string-name>, <string-name><surname>Evangelista</surname><given-names>I</given-names></string-name>, <string-name><surname>De Vivo</surname><given-names>O</given-names></string-name>, <string-name><surname>Nuti</surname><given-names>R</given-names></string-name>, <string-name><surname>Ghio</surname><given-names>S</given-names></string-name>. <article-title>Prognostic significance of an early echocardiographic evaluation of right ventricular dimension and function in Acute heart failure</article-title>. <source>J Card Fail</source>. <year>2020</year>;<volume>26</volume>(<issue>10</issue>):<fpage>813</fpage>‐<lpage>820</lpage>.<pub-id pub-id-type="pmid">31931097</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0026"><string-name><surname>Ghio</surname><given-names>S</given-names></string-name>, <string-name><surname>Guazzi</surname><given-names>M</given-names></string-name>, <string-name><surname>Scardovi</surname><given-names>AB</given-names></string-name>, et al. <article-title>Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction</article-title>. <source>Eur J Heart Fail</source>. <year>2017</year>;<volume>19</volume>(<issue>7</issue>):<fpage>873</fpage>‐<lpage>879</lpage>.<pub-id pub-id-type="pmid">27860029</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0027"><string-name><surname>Lisi</surname><given-names>M</given-names></string-name>, <string-name><surname>Cameli</surname><given-names>M</given-names></string-name>, <string-name><surname>Righini</surname><given-names>FM</given-names></string-name>, et al. <article-title>RV longitudinal deformation correlates with myocardial fibrosis in patients with end‐stage heart failure</article-title>. <source>J Am Coll Cardiol Img</source>. <year>2015</year>;<volume>8</volume>(<issue>5</issue>):<fpage>514</fpage>‐<lpage>522</lpage>.</mixed-citation>
              </ref>
              <ref id="acem14589-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0028"><string-name><surname>Nagy</surname><given-names>VK</given-names></string-name>, <string-name><surname>Széplaki</surname><given-names>G</given-names></string-name>, <string-name><surname>Apor</surname><given-names>A</given-names></string-name>, et al. <article-title>Role of right ventricular global longitudinal strain in predicting early and long‐term mortality in cardiac resynchronization therapy patients</article-title>. <source>PloS One</source>. <year>2015</year>;<volume>10</volume>(<issue>12</issue>):<elocation-id>e0143907</elocation-id>.<pub-id pub-id-type="pmid">26700308</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0029"><string-name><surname>Ojji</surname><given-names>DB</given-names></string-name>, <string-name><surname>Lecour</surname><given-names>S</given-names></string-name>, <string-name><surname>Atherton</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Blauwet</surname><given-names>LA</given-names></string-name>, <string-name><surname>Alfa</surname><given-names>J</given-names></string-name>, <string-name><surname>Sliwa</surname><given-names>K</given-names></string-name>. <article-title>Right ventricular systolic dysfunction is common in hypertensive heart failure: a prospective study in sub‐Saharan Africa</article-title>. <source>PloS One</source>. <year>2016</year>;<volume>11</volume>(<issue>4</issue>):<elocation-id>e0153479</elocation-id>.<pub-id pub-id-type="pmid">27073856</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0030"><string-name><surname>Bilchick</surname><given-names>KC</given-names></string-name>, <string-name><surname>Mejia‐Lopez</surname><given-names>E</given-names></string-name>, <string-name><surname>McCullough</surname><given-names>P</given-names></string-name>, et al. <article-title>Clinical impact of changes in hemodynamic indices of contractile function during treatment of Acute decompensated heart failure</article-title>. <source>J Card Fail</source>. <year>2018</year>;<volume>24</volume>(<issue>1</issue>):<fpage>43</fpage>‐<lpage>50</lpage>.<pub-id pub-id-type="pmid">28712955</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0031"><string-name><surname>Aziz</surname><given-names>EF</given-names></string-name>, <string-name><surname>Kukin</surname><given-names>M</given-names></string-name>, <string-name><surname>Javed</surname><given-names>F</given-names></string-name>, et al. <article-title>Right ventricular dysfunction is a strong predictor of developing atrial fibrillation in acutely decompensated heart failure patients, ACAP‐HF data analysis</article-title>. <source>J Card Fail</source>. <year>2010</year>;<volume>16</volume>(<issue>10</issue>):<fpage>827</fpage>‐<lpage>834</lpage>.<pub-id pub-id-type="pmid">20932465</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0032"><string-name><surname>Dokainish</surname><given-names>H</given-names></string-name>, <string-name><surname>Sengupta</surname><given-names>R</given-names></string-name>, <string-name><surname>Patel</surname><given-names>R</given-names></string-name>, <string-name><surname>Lakkis</surname><given-names>N</given-names></string-name>. <article-title>Usefulness of right ventricular tissue doppler imaging to predict outcome in left ventricular heart failure independent of left ventricular diastolic function</article-title>. <source>Am J Cardiol</source>. <year>2007</year>;<volume>99</volume>(<issue>7</issue>):<fpage>961</fpage>‐<lpage>965</lpage>.<pub-id pub-id-type="pmid">17398192</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0033"><string-name><surname>Grodin</surname><given-names>JL</given-names></string-name>, <string-name><surname>Drazner</surname><given-names>MH</given-names></string-name>, <string-name><surname>Dupont</surname><given-names>M</given-names></string-name>, et al. <article-title>A disproportionate elevation in right ventricular filling pressure, in relation to left ventricular filling pressure, is associated with renal impairment and increased mortality in advanced decompensated heart failure</article-title>. <source>Am Heart J</source>. <year>2015</year>;<volume>169</volume>(<issue>6</issue>):<fpage>806</fpage>‐<lpage>812</lpage>.<pub-id pub-id-type="pmid">26027618</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0034"><string-name><surname>Kjaergaard</surname><given-names>J</given-names></string-name>, <string-name><surname>Akkan</surname><given-names>D</given-names></string-name>, <string-name><surname>Iversen</surname><given-names>KK</given-names></string-name>, <string-name><surname>Kober</surname><given-names>L</given-names></string-name>, <string-name><surname>Torp‐Pedersen</surname><given-names>C</given-names></string-name>, <string-name><surname>Hassager</surname><given-names>C</given-names></string-name>. <article-title>Right ventricular dysfunction as an independent predictor of short‐ and long‐term mortality in patients with heart failure</article-title>. <source>Eur J Heart Fail</source>. <year>2007</year>;<volume>9</volume>(<issue>6–7</issue>):<fpage>610</fpage>‐<lpage>616</lpage>.<pub-id pub-id-type="pmid">17462946</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0035"><string-name><surname>Testani</surname><given-names>JM</given-names></string-name>, <string-name><surname>Khera</surname><given-names>AV</given-names></string-name>, <string-name><surname>St John Sutton</surname><given-names>MG</given-names></string-name>, et al. <article-title>Effect of right ventricular function and venous congestion on cardiorenal interactions during the treatment of decompensated heart failure</article-title>. <source>Am J Cardiol</source>. <year>2010</year>;<volume>105</volume>(<issue>4</issue>):<fpage>511</fpage>‐<lpage>516</lpage>.<pub-id pub-id-type="pmid">20152246</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0036"><string-name><surname>Bosch</surname><given-names>L</given-names></string-name>, <string-name><surname>Lam</surname><given-names>CSP</given-names></string-name>, <string-name><surname>Gong</surname><given-names>L</given-names></string-name>, et al. <article-title>Right ventricular dysfunction in left‐sided heart failure with preserved versus reduced ejection fraction</article-title>. <source>Eur J Heart Fail</source>. <year>2017</year>;<volume>19</volume>(<issue>12</issue>):<fpage>1664</fpage>‐<lpage>1671</lpage>.<pub-id pub-id-type="pmid">28597497</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0037"><string-name><surname>Cameli</surname><given-names>M</given-names></string-name>, <string-name><surname>Righini</surname><given-names>FM</given-names></string-name>, <string-name><surname>Lisi</surname><given-names>M</given-names></string-name>, et al. <article-title>Comparison of right versus left ventricular strain analysis as a predictor of outcome in patients with systolic heart failure referred for heart transplantation</article-title>. <source>Am J Cardiol</source>. <year>2013</year>;<volume>112</volume>(<issue>11</issue>):<fpage>1778</fpage>‐<lpage>1784</lpage>.<pub-id pub-id-type="pmid">24063825</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0038"><string-name><surname>Harrison</surname><given-names>NE</given-names></string-name>, <string-name><surname>Ehrman</surname><given-names>R</given-names></string-name>, <string-name><surname>Favot</surname><given-names>M</given-names></string-name>, et al. <article-title>Right ventricular dysfunction in acute heart failure from emergency department to discharge: predictors and clinical implications</article-title>. <source>Am J Emerg Med</source>. <year>2021</year>;<volume>52</volume>:<fpage>25</fpage>‐<lpage>33</lpage>.<pub-id pub-id-type="pmid">34861517</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0039"><string-name><surname>Dini</surname><given-names>FL</given-names></string-name>, <string-name><surname>Demmer</surname><given-names>RT</given-names></string-name>, <string-name><surname>Simioniuc</surname><given-names>A</given-names></string-name>, et al. <article-title>Right ventricular dysfunction is associated with chronic kidney disease and predicts survival in patients with chronic systolic heart failure</article-title>. <source>Eur J Heart Fail</source>. <year>2012</year>;<volume>14</volume>(<issue>3</issue>):<fpage>287</fpage>‐<lpage>294</lpage>.<pub-id pub-id-type="pmid">22357576</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0040"><string-name><surname>Garcia‐Martin</surname><given-names>A</given-names></string-name>, <string-name><surname>Moya‐Mur</surname><given-names>JL</given-names></string-name>, <string-name><surname>Carbonell‐San Roman</surname><given-names>SA</given-names></string-name>, et al. <article-title>Four chamber right ventricular longitudinal strain versus right free wall longitudinal strain. Prognostic value in patients with left heart disease</article-title>. <source>Cardiol J</source>. <year>2016</year>;<volume>23</volume>(<issue>2</issue>):<fpage>189</fpage>‐<lpage>194</lpage>.<pub-id pub-id-type="pmid">26711464</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0041"><string-name><surname>Guendouz</surname><given-names>S</given-names></string-name>, <string-name><surname>Rappeneau</surname><given-names>S</given-names></string-name>, <string-name><surname>Nahum</surname><given-names>J</given-names></string-name>, et al. <article-title>Prognostic significance and normal values of 2D strain to assess right ventricular systolic function in chronic heart failure</article-title>. <source>Circ J</source>. <year>2012</year>;<volume>76</volume>(<issue>1</issue>):<fpage>127</fpage>‐<lpage>136</lpage>.<pub-id pub-id-type="pmid">22033348</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0042"><string-name><surname>Nochioka</surname><given-names>K</given-names></string-name>, <string-name><surname>Querejeta Roca</surname><given-names>G</given-names></string-name>, <string-name><surname>Claggett</surname><given-names>B</given-names></string-name>, et al. <article-title>Right ventricular function, right ventricular‐pulmonary artery coupling, and heart failure risk in 4 US communities: the atherosclerosis risk in communities (ARIC) study</article-title>. <source>JAMA Cardiol</source>. <year>2018</year>;<volume>3</volume>(<issue>10</issue>):<fpage>939</fpage>‐<lpage>948</lpage>.<pub-id pub-id-type="pmid">30140848</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0043"><string-name><surname>Bistola</surname><given-names>V</given-names></string-name>, <string-name><surname>Parissis</surname><given-names>JT</given-names></string-name>, <string-name><surname>Paraskevaidis</surname><given-names>I</given-names></string-name>, et al. <article-title>Prognostic value of tissue doppler right ventricular systolic and diastolic function indexes combined with plasma B‐type natriuretic peptide in patients with advanced heart failure secondary to ischemic or idiopathic dilated cardiomyopathy</article-title>. <source>Am J Cardiol</source>. <year>2010</year>;<volume>105</volume>(<issue>2</issue>):<fpage>249</fpage>‐<lpage>254</lpage>.<pub-id pub-id-type="pmid">20102927</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0044"><string-name><surname>Frea</surname><given-names>S</given-names></string-name>, <string-name><surname>Pidello</surname><given-names>S</given-names></string-name>, <string-name><surname>Bovolo</surname><given-names>V</given-names></string-name>, et al. <article-title>Prognostic incremental role of right ventricular function in acute decompensation of advanced chronic heart failure</article-title>. <source>Eur J Heart Fail</source>. <year>2016</year>;<volume>18</volume>(<issue>5</issue>):<fpage>564</fpage>‐<lpage>572</lpage>.<pub-id pub-id-type="pmid">26991036</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0045"><string-name><surname>Lee</surname><given-names>H</given-names></string-name>, <string-name><surname>Lee</surname><given-names>SE</given-names></string-name>, <string-name><surname>Park</surname><given-names>CS</given-names></string-name>, et al. <article-title>Hyponatraemia and its prognosis in acute heart failure is related to right ventricular dysfunction</article-title>. <source>Heart</source>. <year>2018</year>;<volume>104</volume>(<issue>20</issue>):<fpage>1670</fpage>‐<lpage>1677</lpage>.<pub-id pub-id-type="pmid">29079633</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0046"><string-name><surname>Yamin</surname><given-names>PP</given-names></string-name>, <string-name><surname>Raharjo</surname><given-names>SB</given-names></string-name>, <string-name><surname>Putri</surname><given-names>VK</given-names></string-name>, <string-name><surname>Hersunarti</surname><given-names>N</given-names></string-name>. <article-title>Right ventricular dysfunction as predictor of longer hospital stay in patients with acute decompensated heart failure: a prospective study in Indonesian population</article-title>. <source>Cardiovasc Ultrasound</source>. <year>2016</year>;<volume>14</volume>(<issue>1</issue>):<fpage>25</fpage>.<pub-id pub-id-type="pmid">27401733</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0047">
                <label>47</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0047"><string-name><surname>Daley</surname><given-names>J</given-names></string-name>, <string-name><surname>Grotberg</surname><given-names>J</given-names></string-name>, <string-name><surname>Pare</surname><given-names>J</given-names></string-name>, et al. <article-title>Emergency physician performed tricuspid annular plane systolic excursion in the evaluation of suspected pulmonary embolism</article-title>. <source>Am J Emerg Med</source>. <year>2017</year>;<volume>35</volume>(<issue>1</issue>):<fpage>106</fpage>‐<lpage>111</lpage>.<pub-id pub-id-type="pmid">27793505</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0048">
                <label>48</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0048"><string-name><surname>Daley</surname><given-names>JI</given-names></string-name>, <string-name><surname>Dwyer</surname><given-names>KH</given-names></string-name>, <string-name><surname>Grunwald</surname><given-names>Z</given-names></string-name>, et al. <article-title>Increased sensitivity of focused cardiac ultrasound for pulmonary embolism in emergency department patients with abnormal vital signs</article-title>. <source>Acad Emerg Med</source>. <year>2019</year>;<volume>26</volume>(<issue>11</issue>):<fpage>1211</fpage>‐<lpage>1220</lpage>.<pub-id pub-id-type="pmid">31562679</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0049">
                <label>49</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0049"><string-name><surname>Alerhand</surname><given-names>S</given-names></string-name>, <string-name><surname>Hickey</surname><given-names>SM</given-names></string-name>. <article-title>Tricuspid annular plane systolic excursion (TAPSE) for risk stratification and prognostication of patients with pulmonary embolism</article-title>. <source>J Emerg Med</source>. <year>2020</year>;<volume>58</volume>(<issue>3</issue>):<fpage>449</fpage>‐<lpage>456</lpage>.<pub-id pub-id-type="pmid">31735658</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0050">
                <label>50</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0050"><string-name><surname>Rutz</surname><given-names>MA</given-names></string-name>, <string-name><surname>Clary</surname><given-names>JM</given-names></string-name>, <string-name><surname>Kline</surname><given-names>JA</given-names></string-name>, <string-name><surname>Russell</surname><given-names>FM</given-names></string-name>. <article-title>Emergency physicians are able to detect right ventricular dilation with good agreement compared to cardiology</article-title>. <source>Acad Emerg Med</source>. <year>2017</year>;<volume>24</volume>(<issue>7</issue>):<fpage>867</fpage>‐<lpage>874</lpage>.<pub-id pub-id-type="pmid">28453186</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0051">
                <label>51</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0051"><string-name><surname>von Elm</surname><given-names>E</given-names></string-name>, <string-name><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name><surname>Egger</surname><given-names>M</given-names></string-name>, <string-name><surname>Pocock</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Gøtzsche</surname><given-names>PC</given-names></string-name>, <string-name><surname>Vandenbroucke</surname><given-names>JP</given-names></string-name>. <article-title>The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies</article-title>. <source>PLoS Med</source>. <year>2007</year>;<volume>4</volume>(<issue>10</issue>):<elocation-id>e296</elocation-id>.<pub-id pub-id-type="pmid">17941714</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0052">
                <label>52</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0052"><string-name><surname>Thygesen</surname><given-names>K</given-names></string-name>, <string-name><surname>Alpert</surname><given-names>JS</given-names></string-name>, <string-name><surname>Jaffe</surname><given-names>AS</given-names></string-name>, et al. <article-title>Fourth universal definition of myocardial infarction (2018)</article-title>. <source>J Am Coll Cardiol</source>. <year>2018</year>;<volume>72</volume>(<issue>18</issue>):<fpage>2231</fpage>‐<lpage>2264</lpage>.<pub-id pub-id-type="pmid">30153967</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0053">
                <label>53</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0053"><string-name><surname>Lang</surname><given-names>RM</given-names></string-name>, <string-name><surname>Bierig</surname><given-names>M</given-names></string-name>, <string-name><surname>Devereux</surname><given-names>RB</given-names></string-name>, et al. <article-title>Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology</article-title>. <source>J Am Soc Echocardiogr</source>. <year>2005</year>;<volume>18</volume>(<issue>12</issue>):<fpage>1440</fpage>‐<lpage>1463</lpage>.<pub-id pub-id-type="pmid">16376782</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0054">
                <label>54</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0054"><string-name><surname>Rudski</surname><given-names>LG</given-names></string-name>, <string-name><surname>Lai</surname><given-names>WW</given-names></string-name>, <string-name><surname>Afilalo</surname><given-names>J</given-names></string-name>, et al. <article-title>Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography</article-title>. <source>J Am Soc Echocardiogr</source>. <year>2010</year>;<volume>23</volume>(<issue>7</issue>):<fpage>685</fpage>‐<lpage>713</lpage>. quiz 786‐688.<pub-id pub-id-type="pmid">20620859</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0055">
                <label>55</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0055"><string-name><surname>Nagueh</surname><given-names>SF</given-names></string-name>, <string-name><surname>Smiseth</surname><given-names>OA</given-names></string-name>, <string-name><surname>Appleton</surname><given-names>CP</given-names></string-name>, et al. <article-title>Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging</article-title>. <source>J Am Soc Echocardiogr</source>. <year>2016</year>;<volume>29</volume>(<issue>4</issue>):<fpage>277</fpage>‐<lpage>314</lpage>.<pub-id pub-id-type="pmid">27037982</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0056">
                <label>56</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0056"><string-name><surname>Hsiao</surname><given-names>SH</given-names></string-name>, <string-name><surname>Lin</surname><given-names>SK</given-names></string-name>, <string-name><surname>Wang</surname><given-names>WC</given-names></string-name>, <string-name><surname>Yang</surname><given-names>SH</given-names></string-name>, <string-name><surname>Gin</surname><given-names>PL</given-names></string-name>, <string-name><surname>Liu</surname><given-names>CP</given-names></string-name>. <article-title>Severe tricuspid regurgitation shows significant impact in the relationship among peak systolic tricuspid annular velocity, tricuspid annular plane systolic excursion, and right ventricular ejection fraction</article-title>. <source>J Am Soc Echocardiogr</source>. <year>2006</year>;<volume>19</volume>(<issue>7</issue>):<fpage>902</fpage>‐<lpage>910</lpage>.<pub-id pub-id-type="pmid">16825000</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0057">
                <label>57</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0057"><string-name><surname>Park</surname><given-names>JH</given-names></string-name>, <string-name><surname>Park</surname><given-names>JJ</given-names></string-name>, <string-name><surname>Park</surname><given-names>JB</given-names></string-name>, <string-name><surname>Cho</surname><given-names>GY</given-names></string-name>. <article-title>Prognostic value of biventricular strain in risk stratifying in patients with Acute heart failure</article-title>. <source>J Am Heart Assoc</source>. <year>2018</year>;<volume>7</volume>(<issue>19</issue>):<elocation-id>e009331</elocation-id>.<pub-id pub-id-type="pmid">30371332</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0058">
                <label>58</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0058"><string-name><surname>Thongprayoon</surname><given-names>C</given-names></string-name>, <string-name><surname>Jadlowiec</surname><given-names>CC</given-names></string-name>, <string-name><surname>Leeaphorn</surname><given-names>N</given-names></string-name>, et al. <article-title>Feature importance of Acute rejection among black kidney transplant recipients by utilizing random Forest analysis: an analysis of the UNOS database</article-title>. <source>Medicines (Basel)</source>. <year>2021</year>;<volume>8</volume>(<issue>11</issue>):<fpage>66</fpage>. doi:<pub-id pub-id-type="doi">10.3390/medicines8110066</pub-id><pub-id pub-id-type="pmid">34822363</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0059">
                <label>59</label>
                <mixed-citation publication-type="book" id="acem14589-cit-0059"><string-name><surname>Frank</surname><given-names>E</given-names></string-name>, <string-name><surname>Harrell</surname><given-names>J</given-names></string-name>. <source>Regression Modeling Strategies</source>. <edition designator="2">2nd ed.</edition><publisher-name>Springer</publisher-name>; <year>2015</year>.</mixed-citation>
              </ref>
              <ref id="acem14589-bib-0060">
                <label>60</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0060"><string-name><surname>Kerr</surname><given-names>KF</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Janes</surname><given-names>H</given-names></string-name>, <string-name><surname>McClelland</surname><given-names>RL</given-names></string-name>, <string-name><surname>Psaty</surname><given-names>BM</given-names></string-name>, <string-name><surname>Pepe</surname><given-names>MS</given-names></string-name>. <article-title>Net reclassification indices for evaluating risk prediction instruments: a critical review</article-title>. <source>Epidemiology</source>. <year>2014</year>;<volume>25</volume>(<issue>1</issue>):<fpage>114</fpage>‐<lpage>121</lpage>.<pub-id pub-id-type="pmid">24240655</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0061">
                <label>61</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0061"><string-name><surname>Hollenberg</surname><given-names>SM</given-names></string-name>, <string-name><surname>Warner Stevenson</surname><given-names>L</given-names></string-name>, <string-name><surname>Ahmad</surname><given-names>T</given-names></string-name>, et al. <article-title>2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure</article-title>. <source>J Am Coll Cardiol</source>. <year>2019</year>;<volume>74</volume>(<issue>15</issue>):<fpage>1966</fpage>‐<lpage>2011</lpage>.<pub-id pub-id-type="pmid">31526538</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0062">
                <label>62</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0062"><string-name><surname>Sax</surname><given-names>DR</given-names></string-name>, <string-name><surname>Rana</surname><given-names>JS</given-names></string-name>, <string-name><surname>Mark</surname><given-names>DG</given-names></string-name>, et al. <article-title>Outcomes among acute heart failure emergency department patients by preserved vs. reduced ejection fraction</article-title>. <source>ESC Heart Failure</source>. <year>2021</year>;<volume>8</volume>(<issue>4</issue>):<fpage>2889</fpage>‐<lpage>2898</lpage>.<pub-id pub-id-type="pmid">33978311</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0063">
                <label>63</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0063"><string-name><surname>Favot</surname><given-names>M</given-names></string-name>, <string-name><surname>Ehrman</surname><given-names>R</given-names></string-name>, <string-name><surname>Gowland</surname><given-names>L</given-names></string-name>, et al. <article-title>Changes in speckle‐tracking‐derived mechanical dispersion index are associated with 30‐day readmissions in acute heart failure</article-title>. <source>Ultrasound J</source>. <year>2019</year>;<volume>11</volume>(<issue>1</issue>):<fpage>9</fpage>.<pub-id pub-id-type="pmid">31359194</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0064">
                <label>64</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0064"><string-name><surname>Collins</surname><given-names>SP</given-names></string-name>, <string-name><surname>Pang</surname><given-names>PS</given-names></string-name>. <article-title>ACUTE heart failure risk stratification</article-title>. <source>Circulation</source>. <year>2019</year>;<volume>139</volume>(<issue>9</issue>):<fpage>1157</fpage>‐<lpage>1161</lpage>.<pub-id pub-id-type="pmid">30857401</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0065">
                <label>65</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0065"><string-name><surname>Koratala</surname><given-names>A</given-names></string-name>, <string-name><surname>Kazory</surname><given-names>A</given-names></string-name>. <article-title>Point of care ultrasonography for objective assessment of heart failure: integration of cardiac, vascular, and extravascular determinants of volume status</article-title>. <source>Cardiorenal Med</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>5</fpage>‐<lpage>17</lpage>.<pub-id pub-id-type="pmid">33477143</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0066">
                <label>66</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0066"><string-name><surname>Pang</surname><given-names>PS</given-names></string-name>, <string-name><surname>Russell</surname><given-names>FM</given-names></string-name>, <string-name><surname>Ehrman</surname><given-names>R</given-names></string-name>, et al. <article-title>Lung ultrasound‐guided emergency Department Management of Acute Heart Failure (BLUSHED‐AHF): a randomized controlled pilot trial</article-title>. <source>JACC Heart Failure</source>. <year>2021</year>;<volume>9</volume>(<issue>9</issue>):<fpage>638</fpage>‐<lpage>648</lpage>.<pub-id pub-id-type="pmid">34246609</pub-id></mixed-citation>
              </ref>
              <ref id="acem14589-bib-0067">
                <label>67</label>
                <mixed-citation publication-type="journal" id="acem14589-cit-0067"><string-name><surname>van Smeden</surname><given-names>M</given-names></string-name>, <string-name><surname>de Groot</surname><given-names>JAH</given-names></string-name>, <string-name><surname>Moons</surname><given-names>KGM</given-names></string-name>, et al. <article-title>No rationale for 1 variable per 10 events criterion for binary logistic regression analysis</article-title>. <source>BMC Med Res Methodol</source>. <year>2016</year>;<volume>16</volume>(<issue>1</issue>):<fpage>163</fpage>.<pub-id pub-id-type="pmid">27881078</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
